



## Review

# Drug targets for COVID-19 therapeutics: Ongoing global efforts

AMBRISH SAXENA 

Indian Institute of Technology Tirupati, Tirupati, India

(Email, [ambrish@iittp.ac.in](mailto:ambrish@iittp.ac.in))

MS received 21 April 2020; accepted 31 May 2020

The current global pandemic COVID-19 caused by the SARS-CoV-2 virus has already inflicted insurmountable damage both to the human lives and global economy. There is an immediate need for identification of effective drugs to contain the disastrous virus outbreak. Global efforts are already underway at a war footing to identify the best drug combination to address the disease. In this review, an attempt has been made to understand the SARS-CoV-2 life cycle, and based on this information potential druggable targets against SARS-CoV-2 are summarized. Also, the strategies for ongoing and future drug discovery against the SARS-CoV-2 virus are outlined. Given the urgency to find a definitive cure, ongoing drug repurposing efforts being carried out by various organizations are also described. The unprecedented crisis requires extraordinary efforts from the scientific community to effectively address the issue and prevent further loss of human lives and health.

**Keywords.** Coronavirus; Covid-19; drug discovery; drug repurposing; drug target; SARS-CoV-2

## 1. Introduction

The advent of the devastating COVID-19 pandemic in 2020 has left more than 5.5 million people infected and more than 340,000 deaths all over the world (Zhou *et al.* 2020a; <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>). These numbers demonstrate the large-scale damage this virus has caused on a global scale. COVID-19, as the World Health Organization (WHO) has designated this disease, is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Du Toit 2020) ([https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)). Since there is no absolute definitive drug or vaccine available that can contain the spread of this deadly virus, the management strategy for the disease is primarily aimed at treating the symptoms (Jin *et al.*

2020). Lack of treatment options has only led to an increased number of fatalities due to the disease (Abbas *et al.* 2020; Down *et al.* 2020).

Academic labs and drug discovery organizations world over are working tirelessly to evaluate compounds that can inhibit the spread of SARS-CoV-2 in humans. To achieve this it is essential to first identify drug targets and subsequently identify and evaluate compounds and biologics that can effectively engage these targets and inhibit the spread (Alexander *et al.* 2020a, b; Dong *et al.* 2020). However, such efforts can be arduous and involve a painstakingly long process. Therefore in parallel, we should also evaluate known antivirals and repurpose them either as single agents or in combinations so that they can effectively contain the spread of the virus (Ahn *et al.* 2020; Hijikata *et al.* 2020; Jeon *et al.* 2020). In order to do this, global concerted efforts are required, and rapid clinical trials need to be conducted to evaluate the role of potential candidate compounds in this particular disease and population setting.

Since the onset of this century, Coronaviruses have created a pandemic-like situation at least at two earlier

---

This article is part of the Topical Collection: COVID-19: Disease Biology & Intervention

events. First was the Severe Acute Respiratory Syndrome (SARS) pandemic at the beginning of the 21st century and then the Middle East Respiratory Syndrome (MERS) outbreak almost a decade before (Al-Omari *et al.* 2019; Centers for Disease and Prevention 2013; Holmes 2003). Both these pandemics were caused by viruses belonging to the Coronavirus family of viruses (Benvenuto *et al.* 2020). In fact, the symptoms of SARS and the current COVID-19 pandemic patients are quite similar, reaffirming the fact that both these viruses are quite similar in their genomic constitution and mode of transmission (Kandeel *et al.* 2020; Kumar *et al.* 2020; Xie and Chen 2020a). However, since the SARS epidemic, the SARS-CoV-2 virus has undergone mutations (Becerra-Flores and Cardozo 2020; Biswas *et al.* 2020; Bzowka *et al.* 2020; Poterico and Mestanza 2020; Yin 2020) and thus the drugs developed against the SARS virus might not very effective in containing the virus spread. In order to understand the drug targets and appreciate the ongoing efforts directed towards the identification of therapies against SARS-CoV-2, it is important to understand the virus biology, mode of transmission and replication cycle. This is especially important since any effective therapy against SARS-CoV-2 should preferably target the stages in the virus life cycle.

In this review, the potential drug targets for drug candidates against SARS-CoV-2 are discussed and an overview of the current status of drug development against SARS-CoV-2 infection is provided. The equally important efforts towards vaccine development are excluded from this review, as this topic is covered in a separate in-depth review (Mukherjee 2020).

### 1.1 Classification of coronaviruses

SARS-CoV-2 is a member of the Coronaviruses (CoV) class of viruses. CoV are essentially positive-stranded RNA viruses and display a crown-like appearance on the surface when observed under an electron microscope. It is due to the presence of this 'crown-like structure' that this class of viruses is called Coronaviruses (*coronam* being the Latin term for crown) (Alanagreh *et al.* 2020; Rehman *et al.* 2020). Structurally, these 'crown-like structures' are glycoprotein present on the viral envelope which facilitate virus entry in the host cells (Coutard *et al.* 2020). There are four known subfamilies of coronaviruses, classified as Alphacoronavirus, Betacoronavirus, Gammacoronavirus and Deltacoronavirus (Li *et al.* 2020a). Although the zoological evolution of coronaviruses is still an

active research subject, it is widely accepted that Alpha- and Betacoronaviruses are predominant in bats and rodents whereas Delta- and Gammacoronavirus gene sources are the avian species (Brussow 2020a; Cascella *et al.* 2020; Coronaviridae Study Group of the International Committee on Taxonomy of 2020).

The causative virus of COVID-19 pandemic, SARS-CoV-2 virus is a part Betacoronavirus subfamily and is believed to have crossed the species barrier to infect humans due to zoonotic transmission (Mackenzie and Smith 2020; Zimmermann and Curtis 2020). The hallmark of coronavirus transcription is the production of multiple sub-genomic RNAs containing sequences corresponding to both genomic ends (Song *et al.* 2020). These viruses utilize RNA-dependent RNA synthesis to generate mRNAs transcribed by the host genome. Genetically, SARS-CoV-2 is a positive-sense, single-stranded RNA virus with a genome size of 30 kb which encodes for two Open Reading Frames (ORFs) (Ceraolo and Giorgi 2020; Dabravolski and Kavalionak 2020; Yang *et al.* 2005). These ORFs are designated as 1a and 1b, and code for protease 3C<sub>1</sub>Pro and PL<sub>1</sub>Pro. These proteases then cleave the polypeptide into 16 non-structural proteins (Nsp) which are essentially viral enzymes involved in replication and packaging of the virus within the host cell and four structural proteins that contribute to the outer structure of the virus (Jean *et al.* 2020; McKee *et al.* 2020; van Boheemen *et al.* 2012). Like other Coronaviruses, the outer surface of the SARS-CoV-2 virus is made of Spike (S) protein, envelope (E) protein, membrane (M) protein and the Nucleocapsid (N) protein. The M and E proteins are involved in virus morphogenesis and assembly. The Spike protein (S) is at the forefront of infection and interacts with the ACE-2 receptor on the host cell surface thereby promoting virus-cell membrane fusion during initiation of viral infection. The Envelope (E) and Membrane (M) protein constitute the cover outside the viral genetic material. Inside the shell of M and E proteins is the RNA which is guarded by the Nucleocapsid protein (Glebov 2020; Nieto-Torres *et al.* 2011; Nieto-Torres *et al.* 2015).

### 1.2 Molecular basis of disease transmission


It is a well-accepted fact that the SARS-CoV-2 transmission is facilitated by respiratory secretions in the form of droplet/aerosol when a person comes in close contact with the infected person (Guo *et al.* 2020a, b). Recent reports suggest that the infection can also spread through stool, urine, and respiratory secretions (Casanova *et al.* 2010; Ding *et al.* 2020; Wang *et al.* 2020b).

As soon as the SARS-CoV-2 virus enters the human body, it establishes a cycle of replication by binding to cell types such as enterocytes and pneumocytes. This virus can also infect tubular renal epithelial cells (Bao *et al.* 2020), immune cells (Annweiler *et al.* 2020) and cerebral neurons (Bilinska *et al.* 2020; Xie and Chen 2020b). The Spike protein present on the surface of SARS-CoV-2 is responsible for the primary establishment of host-protein interaction. The Spike protein binds to the Angiotensin-converting enzyme-2 (ACE-2) receptor present on the host cell plasma membrane (Annweiler *et al.* 2020; Hasan *et al.* 2020b). Post receptor recognition, the viral genome including the Nucleocapsid is released into the cytoplasm of the host cell as shown in figure 1. As mentioned above, the SARS-CoV-2 viral genome has two ORFs: 1a and 1b. These ORFs translate to two polypeptides (PP) Pp1a and Pp1b which in turn hijack the host cellular ribosomes for their own translational process, thereby making a replication-transcription complex (Bojkova *et al.* 2020; Dong *et al.* 2020).

The polypeptide is processed by proteases and this processing results in 16 Non-Structural Proteins (NSPs), and each of these has its own specific function

in replication and transcription (Hillen *et al.* 2020; te Velhuis *et al.* 2012). NSP1 and 2 are involved in the suppression of host gene expression. NSP5 is involved in replication whereas NSP4 and 6 are transmembrane proteins (Kandeel *et al.* 2020; Stobart *et al.* 2013; Zhang *et al.* 2020b). NSP7 and 8 act as primases, while NSP9 is an RNA-binding protein. The dimeric form of NSP9 is critical for viral infection, and disruption of this dimerization could be a potential strategy to inhibit the infection. NSP10 is involved in replication and NSP12 is an RNA-dependent RNA polymerase. NSP12 has helicase activity, NSP14 demonstrates exonuclease activity, and NSP15 has endoribonuclease activity, while NSP16 possesses methyltransferase activity (Athmer *et al.* 2017; Hillen *et al.* 2020; Hu *et al.* 2009; Jia *et al.* 2019; Mirza and Froeyen 2020; Neogi *et al.* 2020).

These NSPs with the help of host machinery translate the RNA coding for the viral Spike, Envelope, Nucleocapsid and Membrane proteins. These proteins then enter the endoplasmic reticulum (ER) – golgi apparatus and are involved in viral assembly and packaging. The viral genome binds to the Nucleocapsid (N) protein and results in the formation of the



**Figure 1.** Stages of SARS-CoV-2 life cycle. Along with the stages arrows point to drugs and candidate drugs active against the drug targets.

ribonucleoprotein complex (RNP) (Cong *et al.* 2017; Gui *et al.* 2017; Narayanan *et al.* 2008; Narayanan *et al.* 2015).

As depicted in figure 1, Coronaviruses exploit the host's endosomal pathway to gain entry in the host cell. As such the virus entry into the host cell is an energetically unfavorable process (Brielle *et al.* 2020), but viruses are able to overcome this barrier due to the low pH environment and pH-dependent endosomal cysteine protease (Du *et al.* 2020; Simmons *et al.* 2011; Zhang *et al.* 2019). Other host proteases, such as transmembrane protease serine 2 (TMPRSS2) and TMPRSS11D (also known as airway trypsin-like protease), are involved in the processing of the Spike protein into its constituent subunits S1 and S2 and promote virus entry at the plasma membrane of the host (Iwata-Yoshikawa *et al.* 2019; Maggio and Corsini 2020; Matsuyama *et al.* 2010). Agents that modify the pH or inhibit these proteases can be potential drug targets for anti-coronavirus therapy (Baglivo *et al.* 2020; Bein *et al.* 2020). Finally, the virus particle is assembled, and it again exploits the host's exosomal pathway and fuses with the plasma membrane resulting in the release of virus particles into the extracellular region. Upon infection, the viral load increases in the host body and this results in an increase in pro-inflammatory cytokines (Alosaimi *et al.* 2020; Conti *et al.* 2020; Magro 2020) and chemokines (Alosaimi *et al.* 2020; Channappanavar and Perlman 2017; Gralinski *et al.* 2018; Skinner *et al.* 2019), which have the potential to damage the lung tissue (Tanaka *et al.* 2013), leading to deterioration of lung function, and finally lung failure (Brussow 2020b).

## 2. Approaches for drug discovery targeting SARS-CoV-2

Antiviral drugs targeting the SARS-CoV-2 can be classified into two major classes, with the first group targeting virus–host interactions or inhibiting viral assembly (Zhou *et al.* 2020b). The other approach would include drugs that modulate broad-spectrum host innate immune responses or interfere with signaling pathways involved in viral replication. These drugs may be capable of engaging host receptors or proteases utilized for viral entry or may impact the endocytosis pathway (2020; Channappanavar and Perlman 2017; Dong *et al.* 2020; Hijikata *et al.* 2020; Jeon *et al.* 2020; Liu *et al.* 2020b; McKee *et al.* 2020; Sanders *et al.* 2020).

Essentially, three general approaches can be utilized for screening of antiviral compounds capable of inhibiting the COVID-19 infection:

### 2.1 Repurposing of antiviral compounds

The first approach is to check existing antiviral compounds and molecules and estimate their effect on viral replication and packaging. Molecules like interferon alpha, beta and gamma, ribavirin and chemical inhibitors of cyclophilin 8 (Ma-Lauer *et al.* 2020; Zhang *et al.* 2020a) can be evaluated for their antiviral activities. These known antivirals have a strategic advantage since they are in active clinical use and their pharmacokinetic and pharmacodynamic properties are well studied. On the flip side, such drugs might lack specificity against SARS-CoV-2, and thus may have severe adverse effects (Ahn *et al.* 2020; Busquet *et al.* 2020).

### 2.2 High-throughput screening of compounds

The second approach involves screening of chemical libraries that constitute compounds targeting transcriptional machinery of various cell lines. High-throughput screening technology has the potential to screen large libraries of 'drug-likely' chemical compounds for chemical entities having antiviral effects. Even libraries of existing drugs can be screened to support drug repurposing efforts, thereby leading to the identification of new functions of many known drug molecules (Berdigaliyev and Aljofan 2020; de Wilde *et al.* 2014; Dyall *et al.* 2014; Kindrachuk *et al.* 2015; Lu *et al.* 2014). Marketed drugs like Lopinavir/ritonavir which was earlier intended to be used in anti-HIV therapy and was subsequently used to treat SARS have emerged as a result of the successful execution of such screening programs (Chu *et al.* 2004; Cvetkovic and Goa 2003). However, a serious disadvantage of this approach is that the 'hits' obtained from such screenings may have immunosuppressive or cytotoxic effects at higher concentrations. Another disadvantage is that the half-maximal effective concentration (EC<sub>50</sub>) of drugs required to be effective against the SARS-CoV-2 infection might exceed the highest serum concentration (C<sub>max</sub>) levels that can be achieved by pharmacological dosing (Mirza and Froeyen 2020).

### 2.3 Inhibition of SARS-CoV-2 replication mediated by siRNA

The third approach could involve the development of specific novel agents resulting from strong basic research around the genomic and biophysical

understanding of the SARS-CoV-2 life cycle. siRNA molecules or inhibitors that have the capability to inhibit specific viral enzymes involved in viral replication cycle, or monoclonal antibodies targeting the host receptor ACE-2 could be the result of such an endeavor (Hasan *et al.* 2020b). Such an approach has the potential to return a large number of virus-specific promising therapies against the SARS-CoV-2 virus. One of the major hurdles in such therapies is the specific drug delivery of these molecules and a lack of understanding of siRNA-based therapy (Lesch *et al.* 2019; Sohrab *et al.* 2018).

### 3. Approaches for drug repurposing

Due to the immense financial implications, resource implications and time implications involved in novel drug discovery process, pharmaceutical companies and researchers in the field are inclining towards and relying on ‘Drug Repurposing’ efforts (Ashburn and Thor 2004). As the name suggests, using this approach, a known drug or an investigational drug candidate drug is studied for new uses that are beyond their scope of original intended medical indication. Some researchers and institutions also term ‘Drug repurposing’ as Drug Repositioning, Drug re-profiling or Drug re-tasking depending on the final outcome of studies (Scannell *et al.* 2012).

This strategy can considerably lower the risk of failure of investigational drugs since the toxicity profile of the drug is already well evaluated and in most cases its adverse effects are well documented (Pammolli *et al.* 2011). More importantly, this strategy can help save time involved in Drug development since the preclinical testing, safety assessment and even formulation development has already been completed for repurposed drugs (Nosengo 2016). Also, since the drugs have undergone clinical trials earlier, repurposed drugs can potentially skip phases 1 and 2 trials, and based on therapeutic indication and adverse effect profile, repurposed drugs can be considered directly for large scale phase 3 trials (Breckenridge and Jacob 2019). Another important use of repurposed drugs is in drug combination therapy as the use of drugs can be modulated by effective novel drug combinations (Urquhart 2018). Also, initial drug repurposing experiments do not require elaborate laboratory settings and most often new indications and combinations can be postulated using *in-silico* approaches (Hurle 2013). At the same time, this exciting approach suffers from some pitfalls and cautious consideration is required


before positioning a drug for a new therapeutic indication. Mostly drug repurposing studies are driven by drug targets and identified drug targets might demonstrate polypharmacology thereby leading to adverse side effects (Aguilera *et al.* 2019; Cheng 2019; Karuppusamy *et al.* 2019). Also in experimental screening studies, usually a higher dose is used and this might lead to misidentification of a compound as active while its corresponding pharmacological dose might be toxic. At the same time the effective plasma concentrations of drugs might be higher than the maximum tolerable pharmacological dose. Moreover, a substantial structural modification of a drug might change its toxicity profile thereby warranting fresh toxicity studies (Colson and Raoult 2016; Strittmatter 2014).

Many pharmaceutical companies are still shy of completely harnessing the potential of drug repurposing due to the attached intellectual property ‘burden’ and the associated costs (Farha and Brown 2019; Fetro and Scherman 2020; Talevi and Bellera 2020; Yildirim *et al.* 2016). Nevertheless, the drug repurposing approaches can be broadly divided into two broad categories: (1) the computational approach, here bioinformatics tools are used to identify new indications for drugs already in use and the approach relies on ‘Big data’ analysis and Artificial Intelligence (AI) (Issa *et al.* 2020; Ke *et al.* 2020; Lee and Chen 2020). (2) The experimental approach, this is a more traditional approach and relies on *in vitro* experiments to postulate new applications of drugs (Cha *et al.* 2018; Martorana *et al.* 2016). Figure 2 shows a hierarchical view of approaches being used for drug repurposing

#### 3.1 Computational approach

Computational approaches for Drug repurposing are largely data-driven and involve a systematic analysis of gene expression, chemical structure, proteomic data or electronic healthcare records. The most commonly used computational approaches include Signature matching (Koudijs *et al.* 2019), computational molecular docking (Pinzi and Rastelli 2019; Trosset and Cave 2019), Genomic association analysis (Cheng *et al.* 2019; Nabirovichkin *et al.* 2020), Pathway or network mapping (Infante *et al.* 2020; Zhou *et al.* 2020b) and retrospective analysis using electronic health records of approved drugs (Karaman and Sippl 2019; Pereira *et al.* 2020; Shi *et al.* 2020b).

**3.1.1 ‘Signature’ matching:** Every drug or investigational drug candidate possesses some unique



**Figure 2.** Hierarchical view of approaches for drug repurposing.

characteristics or ‘signature’ like its transcriptomic effect profile, structural or adverse effect profile and by matching these characteristics/signatures with another disease or drug, repurposing can be achieved (Karaman and Sippl 2019; Koudijs *et al.* 2019). Using this approach for drug repurposing researchers rely on either drug–disease comparison or drug–drug comparison. In the first case, ‘signatures’ of a particular drug’s gene expression profile before and after treatment is compared with the differential gene expression profile obtained similarly by comparing profiles of healthy with the diseased (Jhamb *et al.* 2019; Khosravi *et al.* 2019). One such drug repurposing example that has taken this approach is the topiramate which is normally used as an antiepileptic drug and acts as an agonist for Gamma amino Butyric acid (GABA) activity (Dudley 2011; Dudley *et al.* 2011). Based on studies by Dudley and co-workers using the drug-disease approach, it was established that topiramate can also be used for inflammatory bowel disease (IBD) as it had signatures comparable to prednisolone, the treatment of choice for IBD (Dudley 2011). The drug–drug similarity approach identifies a common mechanism of action for drugs that belong to different classes and are usually structurally dissimilar (Bakal *et al.* 2019; Wu *et al.* 2019; Yang *et al.* 2019).

**3.1.2 Computational molecular docking:** Computational molecular docking is an indispensable tool for Drug repurposing activities (Chen *et al.* 2012; Cicaloni *et al.* 2019). Here, by using structure-based computational strategy, binding efficiency is predicted between the drug and the target molecule (Elfiky 2020). With

this method large- and small-scale screens can be conducted with known drugs against a disease target (Brindha *et al.* 2016; Kitchen *et al.* 2004). However, this technique has its own limitations, such as, for many targets 3D structure is not elucidated or there is a lack of available screen-able macromolecular database that can provide structural information for a varied molecular class of drug (Xia 2017; Zhou *et al.* 2019).

**3.1.3 Network mapping:** Molecular Pathway or Network mapping is one of the most commonly used methods for drug repurposing. Many identified drug targets are not directly druggable as their direct inhibition might lead to severe adverse effects and thus network mapping can inform about the upstream or downstream druggable targets thereby enabling drug repurposing (Oulas *et al.* 2019; Zhou *et al.* 2020b). Based on Gene expression pattern and disease pathology, drug and disease networks can be created using network mapping tools (Gns *et al.* 2019; Janardhan *et al.* 2018). Such maps and networks can open enormous possibilities for drug repurposing.

## 3.2 Artificial intelligence and drug repurposing

Advances in Information technology with Artificial Intelligence (AI) and ‘Big-data analysis’ are revolutionizing drug repurposing efforts and studies (Mucke 2018). With the help of machine learning tools, computational algorithms can be developed that can predict new drug target engagement with far greater accuracy than earlier used methods (Alvarez-Machancoses *et al.*

2020; Kuang *et al.* 2019; Luscher Dias *et al.* 2020; Nabirovichkin *et al.* 2020). Huge data generated by High-throughput Next Gen Sequencing (NGS) from numerous patients when combined with disease characteristics and treatment options can lead to the identification of new disease biomarkers and drug targets (Stupnikov *et al.* 2018; Zai *et al.* 2018). AI-driven supervised machine learning algorithms can implement multiomics and multitask learning to facilitate drug response elicited by engagement of multiple drug targets (Nascimento *et al.* 2019; Nath *et al.* 2018; Saberian *et al.* 2019; Zhao and So 2019). The impact of this technology can be appreciated by evaluating a recent study where a computational methodology was developed that can utilize heterogeneous data from previously described Drug Target interactions to predict new interactions with even greater accuracy. The methodology known as ‘deepDTnet’ can integrate networks connecting multiple drugs with drug targets and disease database with the help of deep learning (a form of machine learning based on AI) (Brasil *et al.* 2019; Monteiro *et al.* 2020; Wen *et al.* 2017; Zeng *et al.* 2020).

### 3.3 Drug repurposing in antiviral drug discovery

The approaches for drug repurposing can also be utilized to scout for drugs that can be effective antivirals. By screening the database of small molecules against viral drug targets using computational methods, drugs or molecules can be identified may possess antiviral activity (Pizzorno *et al.* 2019). Essentially three different scenarios can be discussed to facilitate antiviral drug repurposing: (1) Known target/new virus: In this scenario, an established antiviral drug targeting a specific protein/pathway is found to possess antiviral activity against other viruses. Known viral RNA polymerase Favipiravir and sofosbuvir were initially developed for the treatment of *Influenza virus* and *Hepatitis C virus* (HCV) infection and were repurposed for treatment of *Ebola virus* (Bai and Hsu 2019; Du *et al.* 2020; Johansen *et al.* 2015; Muthaiyan *et al.* 2020; Salata *et al.* 2019; Veljkovic *et al.* 2015) and *Zika virus* infection (Abbasi 2016; Bernatchez *et al.* 2020; Montes-Grajales *et al.* 2020; Mumtaz *et al.* 2017). (2) Known target/new indication: In this scenario, the pharmacological target is implicated to be affected in a new pathogenic infection. In such cases, drugs targeting these proteins can be repurposed as effective antiviral agents. One such example is about the repurposing of anti-cancer agent Imatinib. Cellular

Abelson (ABL) kinase is the target of Imatinib and the same was shown to be active against coronaviruses (Ananthula *et al.* 2018; Coleman *et al.* 2016; Giuliani *et al.* 2018). (3) New target/new indication: This scenario occurs when an approved drug with a specific target is found to target additional viral proteins or targets. Many antimicrobial agents like teicoplanin (Aziz *et al.* 2018; Zhou *et al.* 2016), ivermectin (Chaccour and Rabinovich 2019; Rabinovich 2018), itraconazole (Alhakamy and Md 2019; Pace *et al.* 2016; Schloer *et al.* 2019; Tsubamoto *et al.* 2017) and nitazoxanide (Cao *et al.* 2017; Rossignol 2016) were also found to be active against some viral infections.

## 4. Lessons from SARS: pharmacological interventions

Lessons from SARS and MERS epidemic can be used to develop some therapies for SARS-CoV-2 infection (Zumla *et al.* 2016). Previously used antiviral drugs like oseltamivir, peramivir, zanamivir, ganciclovir, acyclovir and ribavirin are not recommended for COVID-19 treatment (Li *et al.* 2020c; Wang *et al.* 2020b). Also, systemic corticosteroid treatment such as methylprednisolone is not appreciated as a treatment option for SARS-CoV-2 infected patients (Veronese *et al.* 2020). In such a scenario, given the similarity of SARS-CoV and MERS virus along with the SARS-CoV-2 virus, an insight into the treatment options available for SARS and MERS could provide valuable inspirations for Drug discovery and repurposing (Zumla *et al.* 2016). However, for both SARS and MERS, no specific treatment was recommended; rather WHO recommended managing the disease based on patients’ symptoms (Graham *et al.* 2013).

### 4.1 Ribavirin and corticosteroids

In the year 2003, the SARS pandemic, like COVID-19, caught the world by surprise. Early days in the SARS pandemic patients in Hong Kong and Canada were treated with a combination of ribavirin and corticosteroids (Rainer 2004; Tsang *et al.* 2003). However, subsequent reports indicated towards ribavirin’s high rate of toxicity and lack of ability to control the infection spread (Booth and Stewart 2005; Sung *et al.* 2004; Wong *et al.* 2003). Use of corticosteroid, methylprednisolone is controversial as far as SARS was concerned. In multiple cases, dose-related toxicity was observed. The lower dose of methylprednisolone,

250–500mg/day demonstrated some improvement on a subset of critical SARS patients however a prolonged usage in the absence of any specific antimicrobial agent predisposed the patients to disseminated fungal infection (Chan *et al.* 2003a, b; Tsang and Seto 2004; Tsang and Lam 2003) and avascular necrosis (Chan *et al.* 2003a, b). Based on localized, single-center uncontrolled clinical studies, it was recommended that Corticosteroids should only be used as a ‘rescue therapy’ and not as a treatment as it might impair the host viral clearance (Sung *et al.* 2004).

#### 4.2 Interferons

Viral infections such as hepatitis B and C have been successfully treated by Interferon treatment (Christian *et al.* 2004). Since Interferon is also broad-spectrum antiviral, it was used in some single-center, open-labelled, uncontrolled clinical settings against SARS. In these small trials, patients were stable post-treatment with Interferon in combination with corticosteroids. The results pointed out that perhaps with interferon treatment the lung deterioration can be delayed (although this could not be proven statistically) (Zhao *et al.* 2003). Also, post this treatment, improved oxygen saturation levels and lower creatine phosphokinase levels were observed in critically ill patients. However, this warranted properly designed clinical trials globally (Loutfy *et al.* 2003).

#### 4.3 Ritonavir and lopinavir

A combination of viral protease inhibitor, ritonavir 400 mg and lopinavir 100 mg, when administered orally with 12 h interval for 10 to 14 days as standard therapy, yielded the most promising outcome in Hong Kong-based clinical studies (Chan *et al.* 2003a, b). Here the subjects showed a reduction in steroid dependency and nosocomial infections. At the same time reduction in viral load and concomitant increase in peripheral lymphocyte count was observed. This combination appears to be promising and even for COVID-19 as well this combination is being tested in clinical trials. However, some serious adverse effects were also reported from patients undergoing treatment for SARS infection with this combination. Subjects were observed to suffer from pancreatitis, diarrhea, abdominal pain and liver dysfunction among other associated discomforts like abdominal pain, asthenia, headache, nausea, insomnia and skin rash (Chu *et al.* 2004).

### 5. Key CoV targets for drug development and available therapies

As of date, no specific and definite antiviral drug is available for the treatment of CoV-associated pathologies (Barlow *et al.* 2020; Martinez 2020a; McKee *et al.* 2020; Wu *et al.* 2020a). However, some therapeutic agents based on the biology of the virus and some potential drug targets have been identified.

Since the onset of previous global coronavirus pandemics like MERS and SARS, considerable research has gone into the search for suitable drug targets and subsequent drug candidates (Lou *et al.* 2020). Based on this and life cycle stages of SARS-CoV virus, the therapies that have the potential to act on coronaviruses can be divided into five broad categories/approaches:

- (1) Inhibition of virus binding to the host receptor by either chemical compounds or monoclonal antibodies. These agents can block or effectively engage the host's cell surface receptor thereby preventing virus binding and subsequent internalization (Li *et al.* 2019; Salata *et al.* 2019; Shang *et al.* 2020; Tortorici and Veesler 2019).
- (2) Target the viral endocytosis. This process enables the virus to enter the host cell and release its genetic material for further replication and therefore blocking virus-mediated endocytosis is a logical target for antiviral therapy (Baglivo *et al.* 2020; Delvecchio *et al.* 2016; Glebov 2020; Omotade and Roy 2019; Praveen *et al.* 2020).
- (3) Neutralize the virus particle. This can be accomplished by the compounds and antibodies acting on enzymes or functional proteins critical to virus replication and multiplication (Algaissi and Hashem 2020; Goo *et al.* 2020; Pinto *et al.* 2020; Wang *et al.* 2020a; Wu *et al.* 2020b).
- (4) Targeting the viral structural proteins like the membrane, envelope and Nucleocapsid protein thereby blocking virus repackaging (Hijikata *et al.* 2020; Kato *et al.* 2019; Mirza and Froeyen 2020; Saha *et al.* 2020; Zhang *et al.* 2020b).
- (5) Restoration of host's innate immunity by the agents capable of producing virulent factors (Azkur *et al.* 2020; Casanova *et al.* 2020; Encinar and Menendez 2020; Gemmati *et al.* 2020; Mantlo *et al.* 2020; Tufan *et al.* 2020).

Table 1 summarizes the drug targets and compounds active against SARS-CoV-2, their current development status and the pros and cons of the proposed therapy.

**Table 1.** List of probable drug targets against SARS-CoV-2 and compounds/agents effective against these targets

Targeted viral components	Examples	Mechanism of action	Status	Pros	Cons
<i>Inhibition of SARS -CoV-2 fusion/entry</i>					
RBD of the S1 subunit of S	REGN3051 and REGN3048 mAbs	Antibodies target the RBD domain of the S1 subunit	Preclinical	Efficacy demonstrated <i>in vitro</i>	Narrow spectrum
S2 subunit of S	HR2P and P1 peptides	Antiviral peptides that inhibit fusion of S with host cell receptor	Preclinical	anti-HIV peptidol has been marketed	Narrow spectrum
TMPRSS2	Camostat Mesylate	TMPRSS2 inhibitor that blocks the TMPRSS2-entry pathway	Marketed	Promising results <i>in vitro</i> . Effect on patients need to be tested	Broad spectrum. Developed for therapy against SARS
<i>Inhibition of endocytosis</i>					
Endosomal acidification	chloroquine	An antimalarial that sequesters protons in lysosomes to increase the intracellular pH	Marketed	Broad spectrum; many SARS-CoV-2 affected patients show good recovery	No concrete clinical data to suggest efficacy
Clathrin-mediated endocytosis	Oubain	ATP1A1- binding steroids; inhibits clathrin-mediated endocytosis	Marketed	Active against MERS-CoV	May have risk of cardiac toxicity
<i>Inhibition of Viral Enzymes</i>					
3CLpro	Lopinavir	Inhibits 3CLpro activity	Marketed	Broad spectrum	Toxicity Adverse impact on immune system
PLpro	GRL0617	Inhibits PLpro activity	Preclinical	Narrow spectrum	No animal or clinical data available
RdRp	Remdesivir	Nucleotide analogue; Broad spectrum: many viral infections, inhibits viral RNA synthesis	Marketed	Active against SARS-CoV and MERS-CoV at high doses <i>in vitro</i>	Side effects are common and may be severe with high dose regimens
<i>Inhibition of Viral envelope (E), membrane (M), Nucleocapsid (N) and accessory proteins</i>					
E and M Protein	siRNA	Short chains of dsRNA that interfere with the expression of SARS-CoV proteins	Preclinical	Promising <i>in vitro</i> studies.	Optimal delivery method in humans uncertain
N Protein	Pj34	Impairs viral replication	Preclinical	Narrow spectrum Effective <i>in vitro</i> and in animal studies	Optimal delivery method in humans is uncertain
Membrane and Accessory proteins	Lj001 and JL103	Induces membrane damage	Preclinical	Broad spectrum	Anti-CoV activity yet to be demonstrated Unstable physiologically and photo dependent

Also, the present development stage as well as the pros and cons of therapies are listed

### 5.1 Inhibition of SARS -CoV-2 fusion/entry

SARS-CoV-2 utilizes the spike protein present on the viral surface to gain entry into the host cells. The protein–protein interaction that takes place between the subunits of the spike protein and the active site of the

ACE-2 receptor can be targeted to identify an effective treatment strategy (Wrapp 2020). Like other viruses, the coronaviruses also outsmart drugs targeted against them by constantly mutating the active site of spike protein (Becerra-Flores and Cardozo 2020; Chang *et al.* 2020; Goo *et al.* 2020; Qing *et al.* 2020). As a

result, the SARS-CoV-2 spike protein recognizes the ACE-2 receptor more efficiently than the previously studied SARS virus (Albini *et al.* 2020; Chen *et al.* 2020; Dediego *et al.* 2008; Hasan *et al.* 2020a; Mathewson *et al.* 2008). Specifically, the Receptor Binding Domain (RBD) of the spike protein is a critical target for antibody-mediated disruption of binding. Many antibodies demonstrating the ability to disrupt this binding are in preclinical stages of development (Chen *et al.* 2020; Tai *et al.* 2020; Tian *et al.* 2020). Another strategy is to engage and overwhelm the ACE-2 receptor with recombinant human ACE-2 which is normally present on the cell surface. So delivering an excess of the soluble ACE2 helps to neutralize the virus, by competitively binding to SARS-CoV-2 (rhACE2; GSK2586881) (Ameratunga *et al.* 2020; Basit *et al.* 2020). An open-labeled, randomized, controlled pilot clinical trial is in progress to evaluate this approach (NCT04287686).

Apart from the ACE-2 receptor, cellular serine protease TMPRSS2 also plays an important role in facilitating the entry of the virus in host cells (Hoffmann 2020). A clinically proven chemical inhibitor of TMPRSS2, Camostat Mesylate is also able to significantly reduce infection in cell lines of human lung origin (McKee *et al.* 2020; Rahman *et al.* 2020; Shirato *et al.* 2013; Sternberg *et al.* 2020). In addition to this, the heptad repeat 1 (HR1) and heptad repeat 2 (HR2) present on the SARS-CoV-2 have also been implicated in the facilitation of cell membrane fusion. HR2-derived peptides exhibit effective fusion inhibitory activity (Bosch *et al.* 2008; Huang *et al.* 2019; Wang *et al.* 2019; Xia *et al.* 2019a; Xia *et al.* 2019b).

## 5.2 Inhibition of endocytosis

It is known that post fusion of the spike protein with ACE-2 receptor, the virus is ingested in the cells in a pH and receptor-dependent endocytosis (Chu *et al.* 2006; Glebov 2020). Targeting endocytosis can be another potential strategy towards developing potential drug candidates against SARS-CoV-2. Clathrin-mediated endocytosis is regulated by AP-2-associated protein kinase 1 (AAK1) (Uitdehaag *et al.* 2019). Based on library screening, Janus kinase inhibitor Baricitinib was identified as a possible candidate drug for SARS-CoV-2 (Baglivo *et al.* 2020; Cantini *et al.* 2020; Lo Caputo *et al.* 2020). Also, Oubain, another inhibitor of clathrin-mediated, is being tested for its efficacy in drug trials for SARS-CoV-2 positive patients (Sisk *et al.* 2018). Recently, Chloroquine and

its derivative hydroxychloroquine have garnered great interest as a therapy against SARS-CoV-2 infection (Alexander *et al.* 2020a; Alia and Grant-Kels 2020; Arnold and Buckner 2020; Ballout *et al.* 2020; Costanzo *et al.* 2020). Several clinical trials are underway to assess the contribution of chloroquine therapy in inhibiting SARS-CoV-2 viral progression (Keshtkar-Jahromi and Bavari 2020). Also, it was shown *in vitro*, that a derivative of Chloroquine, hydroxychloroquine (EC<sub>50</sub> = 0.72 μM) is far more potent in inhibiting SARS-CoV-2 infection than Chloroquine (EC<sub>50</sub> = 5.47 μM) (Savarino *et al.* 2003; Yao *et al.* 2020). Although the exact molecular mechanism of hydroxychloroquine in the treatment of COVID-19 remains elusive, it is believed that hydroxychloroquine may impair endosome-mediated viral entry or the late stages of viral replication (Devaux *et al.* 2020).

## 5.3 Inhibition of viral enzymes

As a result of aggressive antiviral drug development and discovery programs undertaken in the past, multiple drugs have been developed against viral proteases, polymerases and helicases (Martinez 2020b). Drugs developed against other viral diseases such as Remdesivir (Wang 2020), Favipiravir (Li *et al.* 2020b), Lopinavir/Ritonavir (Beck *et al.* 2020; Costanzo *et al.* 2020; Gyebi *et al.* 2020; Schoergenhofer *et al.* 2020) are presently being evaluated in clinical trials for their efficacy in containing the COVID-19 pandemic. Remdesivir, an antiviral drug developed against Ebola, is an adenosine analog which inserts into viral RNA chains by RNA-dependent RNA polymerases (RdRps) and results in premature transcription termination (Cao *et al.* 2020; Gordon *et al.* 2020). Similarly, Favipiravir and Ribavirin are guanine analogs and are approved for some viral diseases (Costanzo *et al.* 2020; Fan *et al.* 2020). EIDD-2801 is another oral antiviral drug that acts as a nucleotide analog, like Remdesivir, albeit with lower EC<sub>50</sub>, and is orally administrable (Agostini *et al.* 2019). Other antiviral compounds Lopinavir and Ritonavir are protease inhibitors that target 3C-like protease (3CLpro) of SARS-CoV-2 (Bhatnagar *et al.* 2020). The main coronavirus protease, 3CLpro is responsible for processing the polypeptide to NSPs. Using high-throughput screening for compounds against 3CLpro, four molecules, viz. Prulifloxacin, Tegobuvir, Bictegravir and Nelfinavir, were identified (Barnard *et al.* 2006; De Clercq 2006; Liu *et al.* 2020b).

#### 5.4 Inhibition of viral envelope, membrane, nucleocapsid and accessory proteins

SARS-CoV-2 envelope (E), membrane (M) and Nucleocapsid (N) protein are critical for virus survival and propagation, and therefore such structural proteins are the best drug targets. Since these viral proteins are structurally very different from the host proteins, drug targeting these proteins will have minimal adverse effects. Apart from protecting the viral genome, these structural proteins are also involved in suppressing the host immune system, thereby providing the virus a strategic advantage over the host (Bojkova *et al.* 2020; Borgio *et al.* 2020; Cherian *et al.* 2020). The N protein acts to suppress RNA silencing and suppresses RNA interference-mediated by siRNA. Therefore many siRNA based therapeutics target viral E, M and N protein translation and inhibit viral replication, at least *in vitro* (Nur *et al.* 2015; Sohrab *et al.* 2018; Song *et al.* 2019). However, siRNA-based therapies are still not available for human use due to inherent stability issues and the unavailability of reliable delivery methods (De Clercq 2006).

The E protein also serves as an ion channel and this action is inhibited by hexamethylene amiloride (Pervushin *et al.* 2009). Another chemical inhibitor PJ34 targets the unique ribonucleotide-binding pocket at the N-terminal domain of N protein (Lin *et al.* 2014). It is important to note that most of these inhibitors were designed against the SARS virus; due to the mutations in the SARS-CoV-2 virus, such inhibitors may not be as effective in fighting against the ongoing COVID-19 pandemic.

LJ001 and LJ003 are broad-spectrum antiviral compounds that not only inhibit viral entry in the host cells but also damage the viral membrane by producing singlet oxygen molecules. Unfortunately, LJ001 is physiologically unstable and is photo-dependent (Barlow *et al.* 2020). Nevertheless, LJ001 defines a new class of antiviral compounds, and further research into this class of compounds will yield encouraging results.

#### 5.5 Suppression of excessive inflammatory response

A well-orchestrated cytokine response is critical for the host immune response. It has been reported that some SARS-CoV-2 infected patients demonstrate a hyper-inflammatory response, possibly due to deregulated cytokine response. It was reported that COVID-19 patients in the ICU had high cytokines in plasma when

compared with non-ICU patients, suggesting that cytokine dysregulation is involved in the severe form of COVID-19 disease (Channappanavar and Perlman 2020; Liu *et al.* 2020c). Additionally, SARS-CoV-2-infected patients admitted in ICU display increased levels of GM-CSF and IL6<sup>+</sup>CD4<sup>+</sup>T cells when compared to ICU naïve patients (Boettcher *et al.* 2007). The above facts point to the possibility that inhibition of excessive inflammatory response might reduce the severity of COVID-19 disease. Corticosteroids are known to have excellent pharmacological potential in suppressing systemic inflammation (Liu *et al.* 2020a; Zha *et al.* 2020). However, their use in COVID-19 patients is still debatable and requires a detailed study.

It has been demonstrated that after the onset of SARS-CoV-2 infection, CD4<sup>+</sup>T Cells are activated to produce GM-CSF and other inflammatory cytokines, thus resulting in further induction of CD14<sup>+</sup>CD16<sup>+</sup> monocytes with high expression of interleukin 6 (IL-6) (Conti *et al.* 2020; Liu *et al.* 2020a). This observation leads to the possibility that by blocking the IL-6 receptor we could potentially reduce immune stress caused by SARS-CoV-2. In line with this observation, a multicenter, randomized, controlled clinical trial is currently underway using an IL-6 receptor-specific antibody Tocilizumab (Li *et al.* 2020d) (NCT04315480).

Another recent advance in COVID -19 treatments is the Convalescent plasma treatment. With infection rates growing and no specific therapy available, therapy with convalescent plasma (CP) has been proposed as a principal treatment. In this therapy, the plasma obtained from a donor recovered from the disease is used to develop humoral immunity against SARS-CoV-2-infected patients. The plasma from the donor patient acts as a source of human antibodies against the infection (Jawhara 2020; Shi *et al.* 2020a, b). However, large scale human trials need to be conducted to better understand and evaluate CP as a method of treatment for COVID-19.

## 6. Current efforts from top pharmaceutical companies

Many pharmaceutical giants have now jumped into the race to find a drug for SARS-CoV-2 infected patients. Given the high number of fatalities across the globe, even regulatory authorities are giving rapid approvals to conduct clinical trials for promising candidate drugs. Table 2 shows a list of companies that are conducting clinical trials or are seeking approval from regulatory

**Table 2.** List of companies actively involved in finding a drug to treat SARS-CoV-2 patients

Company/ organization	Candidate drug	Development phase	Current status and plans	Timelines
Gilead	Remdesivir	III	Remdesivir is now being tested in five Covid-19 clinical trials that have been set up at lightning speed	CT is anticipated to be completed by end of April 2020
Sanofi	Hydroxychloroquine	Preclinical	Conduct additional CTs and supply millions of doses of an existing anti-malaria product	N.A.
Abbvie	Lopinavir/ritonavir combination	III	Collaboration ongoing with select health authorities and institutions globally to determine antiviral activity against SARS-CoV-2	N.A.
Regeneron	Monoclonal antibody therapy	Preclinical	Aiming to select the top 2 antibodies for a cocktail therapy, which can either be administered to at-risk -vaccine naïve population or as treatment for those already infected	Potential to enter human CT by early summer 2020
Ascleptis	Combination of two antivirals	I	The Chinese company is testing a combination of antivirals, developed against HIV and the other approved for hepatitis C	N.A.
Takeda	Polyclonal antibody therapy	Preclinical	Collaboration with several health and regulatory agencies and health care partners across the globe on polyclonal antibody TAK-888	Program initiated in March 2020
Lilly	Antibody drug	Preclinical	Eli Lilly developing antibody treatments for coronavirus infection. Using a blood sample from a coronavirus survivor Partner company AbCellera identified more than 500 antibodies that might protect against the virus	CTs in humans to be started in the next four months of 2020

The information was collected from the company web sites or press release. CT Clinical Trial, N.A. status not known

authorities to conduct trials. Since the onset of the SARS epidemic, much knowledge was generated about drug targets and some candidate molecules were developed as well (Kumar *et al.* 2017). However, these molecules could not be taken to clinical trials since there were not enough patients suffering from SARS virus by the time these drugs were developed. Nevertheless, this information is of tremendous use since SARS-CoV and SARS-CoV-2 share striking similarities in the genome, replication cycle and even symptoms experienced by patients (Su and Lai 2020). Systemic genomic comparisons have revealed a striking 79% similarity at the nucleotide level between SARS-CoV-2 and SARS-CoV. However, only 72%

nucleotide similarity was observed in the spike (S) protein of both the viruses (Zhang and Holmes 2020). At the biochemical level both the virus display preferential binding to the ACE-2 receptor. Even at the clinical level, the chest X-rays of patients infected with either SARS-CoV or SARS-CoV-2 display multilobar ground glass like opacities. Similarly the CT scan of patients infected with either virus display lobar consolidations (Ceccarelli *et al.* 2020).

However, since the SARS epidemic, the virus has mutated considerably, and as a result, it now has the Spike protein which is quite different from the previous version. This fact makes efforts to find drugs that inhibit virus entry to host cells quite difficult.

Companies are also relying on drug repurposing (Beck *et al.* 2020; Wang *et al.* 2020), like chloroquine from Sanofi is planned to be tested in Coronavirus patients world over. Meanwhile, other companies like Abbvie, Gilead and Regeneron are testing known antiviral in combinations in patients affected with the SARS-CoV-2 virus (<https://www.abbvie.com/coronavirus.html>). This approach provides a strategic advantage to the ongoing efforts, as the pharmacological effect of single drugs is well-studied on the human body. Also, we know the exact mechanism of action and dose regimen for these antivirals. Now using them in combination to inhibit more than 2 drug targets can be a winning combination (Borges do Nascimento *et al.* 2020). Globally, scientists and health authorities are eagerly waiting to interpret the results obtained from these trials. In the meantime, companies like Takeda and Lilly are working on antibody therapy, and evaluating the efficacy of therapeutic molecules at breakneck speed. Under the aegis of WHO, 'SOLIDARITY' clinical trial is underway to evaluate the treatment opportunities available for COVID-19 patients. The trial is being conducted simultaneously in 30 countries and under this trial, four treatment options are being compared against the standard care options for SARS-CoV-2-infected patients. The trial will test the efficacies of Remdesivir and Chloroquine or Hydroxychloroquine as single agents, Lopinavir in combination with Ritonavir, and Lopinavir with Ritonavir plus Interferon beta-1a (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments>).

## 7. Conclusion

Unfortunately, at the time of writing this article there are more than 22,00,000 confirmed patients suffering from SARS-CoV-2 with more than 152,000 reported deaths across the globe.

Novel infectious diseases resulting from the zoonotic transmission of ever-evolving and mutating coronaviruses will continue to pose a global threat to people's lives and the global economy. Today, despite having suffered from two major coronavirus-related outbreaks like SARS and MERS, the world remains underprepared to formidably accept the challenge of a global pandemic like COVID-19. We are still clueless about the handling of the disease and far away from a definite line of treatment against the SARS-CoV-2 virus. It is extremely critical that a concerted effort

across the globe is undertaken to find a robust cure for coronaviruses-related illness. Given the arduous and cost-sensitive road map for novel drug development, it is of utmost importance to develop broad-spectrum antivirals that act on common features of the coronavirus lifecycle. Drug repurposing should be broadened, and more combination drugs should be evaluated in patient trials to allow inhibition of the disease through more than one target. Although there is a lot to learn from the SARS and MERS epidemic, and a lot of research has been performed to develop a suitable cure, the same cannot be applied to COVID-19 due to viral evolution. Across the globe, serious efforts are ongoing to find compounds and drugs that can decrease COVID-19 progression and it is likely that all such prospects have not been covered in this review. WHO in collaboration with Microsoft maintains an active database of ongoing trials and compounds active against SARS-CoV-2 (<https://www.who.int/ictrp/search/en/>).

Extraordinary collaborations and technology exchange in the area of antiviral drug discovery and clinical trials will expedite patient access to more reliable drugs with improved therapeutic potential. This will also considerably reduce time-to-market for candidate drugs. The current ongoing research should lead to more collective drug discovery efforts, where partnership between research institutes and industries will be of paramount importance.

## Acknowledgements

The author would like to acknowledge Dr Vasudharani Devanathan, Asst. Professor, IISER Tirupati, and Dr Harshini Chakravarthi, IISER Tirupati, for critical reading, and Mr Gowthaman Suresh for the figures.

## References

- 2020 Coronavirus: Everyone wins when patents are pooled. *Nature* **581** 240
- Abbas AR, Abbas A, Ali Y and Memon SF 2020 Important considerations regarding the future management of coronavirus (COVID-19). *Int. J. Surg.* **79** 6–7
- Abbasi J 2016 Repurposing drugs to treat Zika. *JAMA* **316** 1636
- Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X *et al.* 2019 Small-molecule antiviral beta-d-N (4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. *J. Virol.* **93** <https://doi.org/10.1128/JVI.01348-19>

- Aguilera E, Alvarez G, Cerecetto H and Gonzalez M 2019 Polypharmacology in the treatment of chagas disease. *Curr. Med. Chem.* **26** 4476–4489
- Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS *et al.* 2020 Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). *J. Microbiol. Biotechnol.* **30** 313–324
- Al-Omari A, Rabaan AA, Salih S, Al-Tawfiq JA and Memish ZA 2019 MERS coronavirus outbreak: implications for emerging viral infections. *Diagn. Microbiol. Infect. Dis.* **93** 265–285
- Alanagreh L, Alzoughool F and Atoum M 2020 The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms. *Pathogens* **9** <https://doi.org/10.3390/pathogens9050331>
- Albini A, Di Guardo G, Noonan DM and Lombardo M 2020 The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. *Intern. Emerg. Med.* <https://doi.org/10.1007/s11739-020-02364-6>
- Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K *et al.* 2020 COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. *J. Clin. Epidemiol.* <https://doi.org/10.1016/j.jclinepi.2020.04.016>
- Alexander SPH, Armstrong J, Davenport AP, Davies J, Faccenda E *et al.* 2020 A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development. IUPHAR Review 29. *Br. J. Pharmacol.* <https://doi.org/10.1111/bph.15094>
- Algaissi A and Hashem AM 2020 Evaluation of MERS-CoV neutralizing antibodies in sera using live virus microneutralization assay. *Methods Mol. Biol.* **2099** 107–116
- Alhakamy NA and Md S 2019 Repurposing itraconazole loaded PLGA nanoparticles for improved antitumor efficacy in non-small cell lung cancers. *Pharmaceutics* **11** <https://doi.org/10.3390/pharmaceutics11120685>
- Alia E and Grant-Kels JM 2020 Does hydroxychloroquine combat COVID-19? A timeline of evidence. *J. Am. Acad. Dermatol.* <https://doi.org/10.1016/j.jaad.2020.04.031>
- Alosaimi B, Hamed ME, Naeem A, Alsharef AA, AlQahtani SY *et al.* 2020 MERS-CoV infection is associated with downregulation of genes encoding Th1 and Th2 cytokines/chemokines and elevated inflammatory innate immune response in the lower respiratory tract. *Cytokine* **126** 154895
- Alvarez-Machancoses O, DeAndres Galiana EJ, Cernea A, Fernandez de la Vina J and Fernandez-Martinez JL 2020 On the role of artificial intelligence in genomics to enhance precision medicine. *Pharmgenom. Pers. Med.* **13** 105–119
- Ameratunga R, Lehnert K, Leung E, Comoletti D, Snell R *et al.* 2020 Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection. *N Z Med. J.* **133** 112–118
- Ananthula HK, Parker S, Touchette E, Buller RM, Patel G *et al.* 2018 Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents. *BMC Pharmacol. Toxicol.* **19** 80
- Annweiler C, Cao Z, Wu Y, Faucon E, Mouhat S *et al.* 2020 Counter-regulatory ‘renin-angiotensin’ system-based candidate drugs to treat COVID-19 diseases in SARS-CoV-2-infected patients. *Infect. Disord. Drug Targets* <https://doi.org/10.2174/1871526520666200518073329>
- Arnold SLM and Buckner F 2020 Hydroxychloroquine for treatment of SARS-CoV-2 Infection? Improving our confidence in a model-based approach to dose selection. *Clin. Transl. Sci.* <https://doi.org/10.1111/cts.12797>
- Ashburn TT and Thor KB 2004 Drug repositioning: identifying and developing new uses for existing drugs. *Nat. Rev. Drug Discov.* **3** 673–683
- Athmer J, Fehr AR, Grunewald M, Smith EC, Denison MR, *et al.* 2017 In situ tagged nsp15 reveals interactions with coronavirus replication/transcription complex-associated proteins. *mBio* **8** <https://doi.org/10.1128/mbio.02320-16>
- Aziz DB, Teo JWP, Dartois V and Dick T 2018 Teicoplanin - tigecycline combination shows synergy against *Mycobacterium abscessus*. *Front. Microbiol.* **9** 932
- Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W *et al.* 2020 Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. *Allergy* <https://doi.org/10.1111/all.14364>
- Baglivo M, Baronio M, Natalini G, Beccari T, Chiurazzi P *et al.* 2020 Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? *Acta Biomed.* **91** 161–164
- Bai JPF and Hsu CW 2019 Drug repurposing for ebola virus disease: principles of consideration and the animal rule. *J. Pharm. Sci.* **108** 798–806
- Bakal G, Kilicoglu H and Kavuluru R 2019 Non-negative matrix factorization for drug repositioning: experiments with the repoDB dataset. *AMIA Annu. Symp. Proc.* **2019** 238–247
- Ballout RA, Sviridov D, Bukrinsky MI and Remaley AT 2020 The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications. *FASEB J.*
- Bao L, Deng W, Huang B, Gao H, Liu J *et al.* 2020 The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature* <https://doi.org/10.1038/s41586-020-2312-y>
- Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ *et al.* 2020 Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. *Pharmacotherapy* <https://doi.org/10.1002/phar.2398>
- Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R *et al.* 2006 Evaluation of immunomodulators, interferons and

- known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice. *Antivir. Chem. Chemother.* **17** 275–284
- Basit A, Ali T and Rehman SU 2020 Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent. *J. Biomol. Struct. Dyn.* <https://doi.org/10.1080/07391102.2020.1768150>
- Becerra-Flores M and Cardozo T 2020 SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate. *Int. J. Clin. Pract.* <https://doi.org/10.1111/ijcp.13525>
- Beck BR, Shin B, Choi Y, Park S and Kang K 2020 Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. *Comput. Struct. Biotechnol. J.* **18** 784–790
- Bein B, Bachmann M, Huggett S and Wegermann P 2020 SARS-CoV-2/COVID-19: evidence-based recommendations on diagnosis and therapy. *Geburtshilfe Frauenheilkd* **80** 491–498
- Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S *et al.* 2020 The 2019-new coronavirus epidemic: evidence for virus evolution. *J. Med. Virol.* **92** 455–459
- Berdigaliyev N and Aljofan M 2020 An overview of drug discovery and development. *Future Med. Chem.* **12** 939–947
- Bernatchez JA, Tran LT, Li J, Luan Y, Siqueira-Neto JL *et al.* 2020 Drugs for the treatment of Zika virus infection. *J. Med. Chem.* **63** 470–489
- Bhatnagar T, Murhekar MV, Soneja M, Gupta N, Giri S *et al.* 2020 Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use. *Indian J. Med. Res.* [https://doi.org/10.4103/ijmr.IJMR\\_502\\_20](https://doi.org/10.4103/ijmr.IJMR_502_20)
- Bilinska K, Jakubowska P, Von Bartheld CS and Butowt R 2020 Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age. *ACS Chem. Neurosci.* <https://doi.org/10.1021/acscchemneuro.0c00210>
- Biswas A, Bhattacharjee U, Chakrabarti AK, Tewari DN, Banu H *et al.* 2020 Emergence of Novel Coronavirus and COVID-19: whether to stay or die out? *Crit. Rev. Microbiol.* <https://doi.org/10.1080/1040841X.2020.1739001>
- Boettcher IC, Steinberg T, Matiassek K, Greene CE, Hartmann K *et al.* 2007 Use of anti-coronavirus antibody testing of cerebrospinal fluid for diagnosis of feline infectious peritonitis involving the central nervous system in cats. *J. Am. Vet. Med. Assoc.* **230** 199–205
- Bojkova D, Klann K, Koch B, Widera M, Krause D *et al.* 2020 Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. *Nature* <https://doi.org/10.1038/41586-020-2332-7>
- Booth CM and Stewart TE 2005 Severe acute respiratory syndrome and critical care medicine: the Toronto experience. *Crit. Care Med.* **33** S53–60
- Borges do Nascimento IJ, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U *et al.* 2020 Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. *J. Clin. Med.* **9** <https://doi.org/10.3390/jcm9040941>
- Borgio JF, Alsuwat HS, Al Otaibi WM, Ibrahim AM, Almandil NB *et al.* 2020 State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2. *Arch. Med. Sci.* **16** 508–518
- Bosch BJ, Rossen JW, Bartelink W, Zuurveen SJ, de Haan CA *et al.* 2008 Coronavirus escape from heptad repeat 2 (HR2)-derived peptide entry inhibition as a result of mutations in the HR1 domain of the spike fusion protein. *J. Virol.* **82** 2580–2585
- Brasil S, Pascoal C, Francisco R, Dos Reis Ferreira V, Videira PA *et al.* 2019 Artificial intelligence (AI) in rare diseases: Is the future brighter? *Genes (Basel)* **10** <https://doi.org/10.3390/genes10120978>
- Breckenridge A and Jacob R 2019 Overcoming the legal and regulatory barriers to drug repurposing. *Nat. Rev. Drug Discov.* **18** 1–2
- Brielle ES, Schneidman-Duhovny D and Linial M 2020 The SARS-CoV-2 exerts a distinctive strategy for interacting with the ACE2 human receptor. *Viruses* **12** <https://doi.org/10.3390/v12050497>
- Brindha S, Sundaramurthi JC, Velmurugan D, Vincent S and Gnanadoss JJ 2016 Docking-based virtual screening of known drugs against murE of *Mycobacterium tuberculosis* towards repurposing for TB. *Bioinformation* **12** 359–367
- Brussow H 2020a The novel coronavirus—a snapshot of current knowledge. *Microb. Biotechnol.* **13** 607–612
- Brussow H 2020b The novel coronavirus—latest findings. *Microb. Biotechnol.* <https://doi.org/10.1111/1751-7915.13592>
- Busquet F, Hartung T, Pallocca G, Rovida C and Leist M 2020 Harnessing the power of novel animal-free test methods for the development of COVID-19 drugs and vaccines. *Arch. Toxicol.* <https://doi.org/10.1007/s00204-020-02787-2>
- Bzowka M, Mitusinska K, Raczynska A, Samol A, Tuszyński JA *et al.* 2020 Structural and evolutionary analysis indicate that the SARS-CoV-2 Mpro is a challenging target for small-molecule inhibitor design. *Int. J. Mol. Sci.* **21** <https://doi.org/10.3390/ijms21093099>
- Cantini F, Niccoli L, Matarrese D, Nicastrì E, Stobbione P *et al.* 2020 Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. *J. Infect.* <https://doi.org/10.1016/j.jinf.2020.04.017>
- Cao RY, Xu YF, Zhang TH, Yang JJ, Yuan Y *et al.* 2017 Pediatric drug nitazoxanide: a potential choice for control of Zika. *Open Forum Infect. Dis.* **4** ofx009 <https://doi.org/10.1093/ofid/ofx009>
- Cao YC, Deng QX and Dai SX 2020 Remdesivir for severe acute respiratory syndrome coronavirus 2 causing

- COVID-19: an evaluation of the evidence. *Travel. Med. Infect. Dis.* <https://doi.org/10.1016/j.tmaid.2020.101647>
- Casanova JL, Su HC and Effort CHG 2020 A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. *Cell* <https://doi.org/10.1016/j.cell.2020.05.016>
- Casanova LM, Jeon S, Rutala WA, Weber DJ and Sobsey MD 2010 Effects of air temperature and relative humidity on coronavirus survival on surfaces. *Appl. Environ. Microbiol.* **76** 2712–2717
- Cascella M, Rajnik M, Cuomo A, Dulebohn SC and Di Napoli R 2020 Features, evaluation and treatment coronavirus (COVID-19). In: *StatPearls* (Ed) Treasure Island (FL)
- Ceccarelli M, Berretta M, Venanzi Rullo E, Nunnari G and Cacopardo B 2020 Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet? *Eur. Rev. Med. Pharmacol. Sci.* **24** 2781–2783
- Centers for Disease C and Prevention 2013 Update: severe respiratory illness associated with Middle East Respiratory Syndrome Coronavirus (MERS-CoV)—worldwide, 2012–2013. *MMWR Morb. Mortal Wkly. Rep.* **62** 480–483
- Ceraolo C and Giorgi FM 2020 Genomic variance of the 2019-nCoV coronavirus. *J. Med. Virol.* **92** 522–528
- Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J *et al.* 2018 Drug repurposing from the perspective of pharmaceutical companies. *Br. J. Pharmacol.* **175** 168–180 <https://doi.org/10.1111/bph.13798>
- Chaccour C and Rabinovich NR 2019 Advancing the repurposing of ivermectin for malaria. *Lancet* **393** 1480–1481
- Chan KS, Lai ST, Chu CM, Tsui E, Tam CY *et al.* 2003 Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. *Hong Kong Med. J.* **9** 399–406
- Chan PK, Ip M, Ng KC, Rickjason CW, Wu A *et al.* 2003 Severe acute respiratory syndrome-associated coronavirus infection. *Emerg. Infect. Dis.* **9** 1453–1454
- Chang TJ, Yang DM, Wang ML, Liang KH, Tsai PH *et al.* 2020 Genomic Analysis and Comparative Multiple Sequence of SARS-CoV2. *J. Chin. Med. Assoc.* <https://doi.org/10.1097/JCMA.0000000000000335>
- Channappanavar R and Perlman S 2017 Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol.* **39** 529–539
- Channappanavar R and Perlman S 2020 Evaluation of activation and inflammatory activity of myeloid cells during pathogenic human coronavirus infection. *Methods Mol. Biol.* **2099** 195–204
- Chen L, Morrow JK, Tran HT, Phatak SS, Du-Cuny L *et al.* 2012 From laptop to benchtop to bedside: structure-based drug design on protein targets. *Curr. Pharm. Des.* **18** 1217–1239
- Chen WH, Hotez PJ and Bottazzi ME 2020 Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. *Hum. Vaccin. Immunother.* <https://doi.org/10.1080/21645515.2020.1740560>
- Cheng F 2019 In Silico oncology drug repositioning and polypharmacology. *Methods Mol. Biol.* **1878** 243–261
- Cheng F, Lu W, Liu C, Fang J, Hou Y *et al.* 2019 A genome-wide positioning systems network algorithm for in silico drug repurposing. *Nat. Commun.* **10** 3476
- Cherian SS, Agrawal M, Basu A, Abraham P, Gangakhedkar RR *et al.* 2020 Perspectives for repurposing drugs for the coronavirus disease 2019. *Indian J. Med. Res.* **151** 160–171
- Christian MD, Poutanen SM, Loutfy MR, Muller MP and Low DE 2004 Severe acute respiratory syndrome. *Clin. Infect. Dis.* **38** 1420–1427
- Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH *et al.* 2004 Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax.* **59** <https://doi.org/10.1136/thorax.2003.012658>
- Chu VC, McElroy LJ, Chu V, Bauman BE and Whittaker GR 2006 The avian coronavirus infectious bronchitis virus undergoes direct low-pH-dependent fusion activation during entry into host cells. *J. Virol.* **80** 3180–3188
- Cicaloni V, Trezza A, Pettini F and Spiga O 2019 Applications of in silico methods for design and development of drugs targeting protein-protein interactions. *Curr. Top Med. Chem.* **19** 53–554
- Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM *et al.* 2016 Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion. *J. Virol.* **90** 8924–8933
- Colson P and Raoult D 2016 Fighting viruses with antibiotics: an overlooked path. *Int. J. Antimicrob. Agents* **48** 349–352
- Cong Y, Kriegenburg F, de Haan CAM and Reggiori F 2017 Coronavirus nucleocapsid proteins assemble constitutively in high molecular oligomers. *Sci. Rep.* **7** 5740
- Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R *et al.* 2020 Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J. Biol. Regul. Homeost. Agents* **34** <https://doi.org/10.23812/conti-e>
- Coronaviridae Study Group of the International Committee on Taxonomy of V 2020 The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat. Microbiol.* **5** 536–544
- Costanzo M, De Giglio MAR and Roviello GN 2020 SARS CoV-2: Recent reports on antiviral therapies based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxy-chloroquine, Remdesivir, Favipiravir and other drugs for

- the treatment of the new coronavirus. *Curr. Med. Chem.* <https://doi.org/10.2174/0929867327666200416131117>
- Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG *et al.* 2020 The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Res.* **176** 104742
- Cvetkovic RS and Goa KL 2003 Lopinavir/ritonavir: a review of its use in the management of HIV infection. *Drugs* **63** <https://doi.org/10.2165/00003495-200363080-00004>
- Dabravolski SA and Kavalionak YK 2020 SARS-CoV-2: Structural diversity, phylogeny, and potential animal host identification of spike glycoprotein. *J. Med. Virol.* <https://doi.org/10.1002/jmv.25976>
- De Clercq E 2006 Potential antivirals and antiviral strategies against SARS coronavirus infections. *Expert Rev. Anti Infect. Ther.* **4** 291–302
- de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S *et al.* 2014 Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. *Antimicrob. Agents Chemother.* **58** 4875–4884
- Dediego ML, Pewe L, Alvarez E, Rejas MT, Perlman S *et al.* 2008 Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. *Virology* **376** 379–389
- Delvecchio R, Higa LM, Pezzuto P, Valadao AL, Garcez PP *et al.* 2016 Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models. *Viruses* **8** <https://doi.org/10.3390/v8120322>
- Devaux CA, Rolain JM, Colson P and Raoult D 2020 New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? *Int. J. Antimicrob. Agents* <https://doi.org/10.1016/j.ijantimicag.2020.105938>
- Ding Q, Lu P, Fan Y, Xia Y and Liu M 2020 The clinical characteristics of pneumonia patients coinfecting with 2019 novel coronavirus and influenza virus in Wuhan, China. *J. Med. Virol.* <https://doi.org/10.1002/jmv.25781>
- Dong L, Hu S and Gao J 2020 Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discov. Ther.* **14** 58–60
- Down B, Kulkarni S, Ahmed Khan AH, Barker B and Tang I 2020 Novel coronavirus (COVID-19) infection: What a doctor on the frontline needs to know. *Ann. Med. Surg. (Lond.)* <https://doi.org/10.1016/j.amsu.2020.05.014>
- Du Toit A 2020 Outbreak of a novel coronavirus. *Nat. Rev. Microbiol.* **18** 123
- Du X, Zuo X, Meng F, Wu F, Zhao X *et al.* 2020 Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. *Biochem. Biophys. Res. Commun.* **522** 862–868
- Dudley JT 2011 Computational repositioning of the anti-convulsant topiramate for inflammatory bowel disease. *Sci. Transl. Med.* **3**
- Dudley JT, Deshpande T and Butte AJ 2011 Exploiting drug-disease relationships for computational drug repositioning. *Brief Bioinform.* **12**
- Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR *et al.* 2014 Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. *Antimicrob. Agents Chemother.* **58** 4885–4893
- Elfiky AA 2020 Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. *Life Sci.* **253** 117592
- Encinar JA and Menendez JA 2020 Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA. *Viruses* **12** <https://doi.org/10.3390/v12050525>
- Fan HH, Wang LQ, Liu WL, An XP, Liu ZD *et al.* 2020 Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. *Chin. Med. J. (Engl.)* <https://doi.org/10.1097/cm9.0000000000000797>
- Farha MA and Brown ED 2019 Drug repurposing for antimicrobial discovery. *Nat. Microbiol.* **4** 565–577
- Fetro C and Scherman D 2020 Drug repurposing in rare diseases: Myths and reality. *Therapie* **75** 157–160
- Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G *et al.* 2020 COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 compared to the single X-chromosome in males? *Int. J. Mol. Sci.* **21** <https://doi.org/10.3390/ijms21103474>
- Giuliani S, Silva AC, Borba J, Ramos PIP, Paveley RA *et al.* 2018 Computationally-guided drug repurposing enables the discovery of kinase targets and inhibitors as new schistosomicidal agents. *PLoS Comput. Biol.* **14** e1006515
- Glebov OO 2020 Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing. *FEBS J.* <https://doi.org/10.1111/febs.15369>
- Gns HS, Gr S, Murahari M and Krishnamurthy M 2019 An update on drug repurposing: re-written saga of the drug's fate. *Biomed. Pharmacother.* **110** 700–716
- Goo J, Jeong Y, Park YS, Yang E, Jung DI *et al.* 2020 Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein. *Virus Res.* **278** 197863
- Gordon CJ, Tchesnokov EP, Feng JY, Porter DP and Gotte M 2020 The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. *J. Biol. Chem.* **295** 4773–4779
- Graham RL, Donaldson EF and Baric RS 2013 A decade after SARS: strategies for controlling emerging coronaviruses. *Nat. Rev. Microbiol.* **11** 836–848

- Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K *et al.* 2018 Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. *mBio* **9** <https://doi.org/10.1128/mbio.01753-18>
- Gui M, Liu X, Guo D, Zhang Z, Yin CC *et al.* 2017 Electron microscopy studies of the coronavirus ribonucleoprotein complex. *Protein Cell* **8** 219–224
- Guo J, Huang Z, Lin L and Lv J 2020a Coronavirus Disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. *J. Am. Heart Assoc.* **9** e016219
- Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD *et al.* 2020b The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. *Mil. Med. Res.* **7** 11
- Gyebi GA, Ogunro OB, Adegunloye AP, Ogunyemi OM and Afolabi SO 2020 Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL(pro)): an in silico screening of alkaloids and terpenoids from African medicinal plants. *J. Biomol. Struct. Dyn.* <https://doi.org/10.1080/07391102.2020.1764868>
- Hasan A, Paray BA, Hussain A, Qadir FA, Attar F *et al.* 2020a A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin. *J. Biomol. Struct. Dyn.* <https://doi.org/10.1080/07391102.2020.1754293>
- Hasan A, Paray BA, Hussain A, Qadir FA, Attar F *et al.* 2020b A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin. *J. Biomol. Struct. Dyn.* <https://doi.org/10.1080/07391102.2020.1754293>
- Hijikata A, Shionyu-Mitsuyama C, Nakae S, Shionyu M, Ota M *et al.* 2020 Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs. *FEBS Lett.* <https://doi.org/10.1002/1873-3468.13806>
- Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D *et al.* 2020 Structure of replicating SARS-CoV-2 polymerase. *Nature* <https://doi.org/10.1038/s41586-020-2368-8>
- Hoffmann M 2020 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* **181** <https://doi.org/10.1016/j.cell.2020.03.025>
- Holmes KV 2003 SARS coronavirus: a new challenge for prevention and therapy. *J. Clin. Invest.* **111** 1605–1609
- Hu T, Zhang Y, Li L, Wang K, Chen S *et al.* 2009 Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure. *Virology* **388** 324–334
- Huang X, Li M, Xu Y, Zhang J, Meng X *et al.* 2019 Novel gold nanorod-based hr1 peptide inhibitor for middle east respiratory syndrome coronavirus. *ACS Appl. Mater. Interfaces* **11** 19799–19807
- Hurle MR 2013 Computational drug repositioning: from data to therapeutics. *Clin. Pharmacol. Ther.* **93**
- Infante T, Del Viscovo L, De Rimini ML, Padula S, Caso P *et al.* 2020 Network medicine: a clinical approach for precision medicine and personalized therapy in coronary heart disease. *J. Atheroscler. Thromb.* **27** 279–302
- Issa NT, Stathias V, Schurer S and Dakshanamurthy S 2020 Machine and deep learning approaches for cancer drug repurposing. *Semin. Cancer Biol.* <https://doi.org/10.1016/j.semcancer.2019.12.01>
- Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M *et al.* 2019 TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. *J. Virol.* **93** <https://doi.org/10.1128/JVI.01815-18>
- Janardhan S, Dubovskaja V, Lagunin A, Rao BV, Sastry GN *et al.* 2018 Recent advances in the development of pharmaceutical agents for metabolic disorders: a computational perspective. *Curr. Med. Chem.* **25** 5432–5463
- Jawhara S 2020 Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? *Int. J. Mol. Sci.* **21** <https://doi.org/10.3390/ijms21072272>
- Jean SS, Lee PI and Hsueh PR 2020 Treatment options for COVID-19: The reality and challenges. *J. Microbiol. Immunol. Infect.* <https://doi.org/10.1016/j.jmii.2020.03.034>
- Jeon S, Ko M, Lee J, Choi I, Byun SY *et al.* 2020 Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. *Antimicrob. Agents Chemother.* <https://doi.org/10.1128/AAC.00819-20>
- Jhamb D, Magid-Slav M, Hurle MR and Agarwal P 2019 Pathway analysis of GWAS loci identifies novel drug targets and repurposing opportunities. *Drug Discov. Today* **24** 1232–1236
- Jia Z, Yan L, Ren Z, Wu L, Wang J *et al.* 2019 Delicate structural coordination of the Severe Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysis. *Nucl. Acids Res.* **47** 6538–6550
- Jin YH, Cai L, Cheng ZS, Cheng H, Deng T *et al.* 2020 A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). *Mil. Med. Res.* **7**
- Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM *et al.* 2015 A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. *Sci. Transl. Med.* **7** 290ra289
- Kandeel M, Ibrahim A, Fayez M and Al-Nazawi M 2020 From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. *J. Med. Virol.* <https://doi.org/10.1002/jmv.25754>
- Karaman B and Sippl W 2019 Computational drug repurposing: current trends. *Curr. Med. Chem.* **26** 5389–5409

- Karuppasamy R, Veerappapillai S, Maiti S, Shin WH and Kihara D 2019 Current progress and future perspectives of polypharmacology: From the view of non-small cell lung cancer. *Semin. Cancer Biol.* <https://doi.org/10.1016/j.semcancer.2019.10.019>
- Kato T, Takami Y, Kumar Deo V and Park EY 2019 Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells. *J. Biotechnol.* **306** 177–184
- Ke YY, Peng TT, Yeh TK, Huang WZ, Chang SE *et al.* 2020 Artificial intelligence approach fighting COVID-19 with repurposing drugs. *Biomed. J.* <https://doi.org/10.1016/j.bj.2020.05.001>
- Keshkar-Jahromi M and Bavari S 2020 A call for randomized controlled trials to test the efficacy of chloroquine and hydroxychloroquine as therapeutics against novel coronavirus disease (COVID-19). *Am. J. Trop. Med. Hyg.* <https://doi.org/10.4269/ajtmh.20-0230>
- Khosravi A, Jayaram B, Goliaei B and Masoudi-Nejad A 2019 Active repurposing of drug candidates for melanoma based on GWAS, PheWAS and a wide range of omics data. *Mol. Med.* **25** 30
- Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR *et al.* 2015 Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. *Antimicrob. Agents Chemother.* **59** 1088–1099
- Kitchen DB, Decornez H, Furr JR and Bajorath J 2004 Docking and scoring in virtual screening for drug discovery: methods and applications. *Nat. Rev. Drug Discov.* **3**
- Koudijs KKM, Terwisscha van Scheltinga AGT, Bohringer S, Schimmel KJM and Guchelaar HJ 2019 Transcriptome signature reversion as a method to reposition drugs against cancer for precision oncology. *Cancer J.* **25** 116–120
- Kuang Z, Bao Y, Thomson J, Caldwell M, Peissig P *et al.* 2019 A machine-learning-based drug repurposing approach using baseline regularization. *Methods Mol. Biol.* **1903** 255–267
- Kumar S, Maurya VK, Prasad AK, Bhatt MLB and Saxena SK 2020 Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). *Virusdisease* **31** 13–21
- Kumar V, Shin JS, Shie JJ, Ku KB, Kim C *et al.* 2017 Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL(Pro) inhibitors. *Antiviral Res.* **141** 101–106
- Lee CY and Chen YP 2020 Prediction of drug adverse events using deep learning in pharmaceutical discovery. *Brief Bioinform.* <https://doi.org/10.1093/bib/bbaa040>
- Lesch M, Luckner M, Meyer M, Weege F, Gravenstein I *et al.* 2019 RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals. *PLoS Pathog.* **15** e1007601
- Li C, Yang Y and Ren L 2020a Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species. *Infect. Genet. Evol.* **82** 104285
- Li CC, Wang XJ and Wang HR 2019 Repurposing host-based therapeutics to control coronavirus and influenza virus. *Drug Discov. Today* **24** 726–736
- Li H, Wang YM, Xu JY and Cao B 2020b Potential antiviral therapeutics for 2019 Novel Coronavirus. *Chin. J. Tuberc. Respir. Dis.* **43**
- Li H, Wang YM, Xu JY and Cao B 2020c [Potential antiviral therapeutics for 2019 Novel Coronavirus]. *Zhonghua Jie He He Hu Xi Za Zhi* **43** 170–172
- Li H, Zhou Y, Zhang M, Wang H, Zhao Q *et al.* 2020d Updated approaches against SARS-CoV-2. *Antimicrob. Agents Chemother.* <https://doi.org/10.1128/AAC.00483-20>
- Lin SY, Liu CL, Chang YM, Zhao J, Perlman S *et al.* 2014 Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target. *J. Med. Chem.* **57** 2247–2257
- Liu B, Li M, Zhou Z, Guan X and Xiang Y 2020a Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? *J. Autoimmun.* <https://doi.org/10.1016/j.jaut.2020.102452>
- Liu S, Zheng Q and Wang Z 2020b Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus. *Bioinformatics* <https://doi.org/10.1093/bioinformatics/btaa224>
- Liu Y, Zhang C, Huang F, Yang Y, Wang F *et al.* 2020c 2019-novel coronavirus (2019-nCoV) infections trigger an exaggerated cytokine response aggravating lung injury
- Lo Caputo S, Corso G, Clerici M and Santantonio TA 2020 Baricitinib: a chance to treat COVID-19? *J. Med. Virol.* <https://doi.org/10.1002/jmv.26033>
- Lou J, Tian SJ, Niu SM, Kang XQ, Lian HX *et al.* 2020 Coronavirus disease 2019: a bibliometric analysis and review. *Eur. Rev. Med. Pharmacol. Sci.* **24** 3411–3421
- Loutfy MR, Blatt LM, Siminovitsh KA, Ward S, Wolff B *et al.* 2003 Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. *JAMA* **290** 3222–3228
- Lu L, Liu Q, Zhu Y, Chan KH, Qin L *et al.* 2014 Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. *Nat. Commun.* **5** 3067
- Luscher Dias T, Schuch V, Beltrao-Braga PCB, Martins-de-Souza D, Brentani HP *et al.* 2020 Drug repositioning for psychiatric and neurological disorders through a network medicine approach. *Transl. Psychiatry* **10** 141
- Ma-Lauer Y, Zheng Y, Malesevic M, von Brunn B, Fischer G *et al.* 2020 Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. *Antiviral Res.* **173** 104620

- Mackenzie JS and Smith DW 2020 COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don't. *Microbiol. Aust.* <https://doi.org/10.1071/MA20013>
- Maggio R and Corsini GU 2020 Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection. *Pharmacol. Res.* **157** 104837
- Magro G 2020 SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc. *Cytokine X* <https://doi.org/10.1016/j.cytok.2020.100029>
- Mantlo E, Bukreyeva N, Maruyama J, Paessler S and Huang C 2020 Antiviral activities of type I interferons to SARS-CoV-2 infection. *Antiviral Res.* **179** 104811
- Martinez MA 2020a Compounds with therapeutic potential against novel respiratory 2019 coronavirus. *Antimicrob. Agents Chemother.* **64** <https://doi.org/10.1128/aac.00399-20>
- Martinez MA 2020b Compounds with therapeutic potential against novel respiratory 2019 coronavirus. *Antimicrob. Agents Chemother.* <https://doi.org/10.1128/AAC.00399-20>
- Martorana A, Perricone U and Lauria A 2016 The repurposing of old drugs or unsuccessful lead compounds by in silico approaches: new advances and perspectives. *Curr. Top Med. Chem.* **16** 2088–2106
- Mathewson AC, Bishop A, Yao Y, Kemp F, Ren J *et al.* 2008 Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2. *J. Gen. Virol.* **89** 2741–2745
- Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M *et al.* 2010 Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. *J. Virol.* **84** 12658–12664
- McKee DL, Sternberg A, Stange U, Laufer S and Naujokat C 2020 Candidate drugs against SARS-CoV-2 and COVID-19. *Pharmacol. Res.* **157** 104859
- Mirza MU and Froeyen M 2020 Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. *J. Pharm. Anal.* <https://doi.org/10.1016/j.jpha.2020.04.008>
- Monteiro NRC, Ribeiro B and Arrais J 2020 Drug-target interaction prediction: end-to-end deep learning approach. *IEEE/ACM Trans. Comput. Biol. Bioinform.* <https://doi.org/10.1109/TCBB.2020.2977335>
- Montes-Grajales D, Puerta-Guardo H, Espinosa DA, Harris E, Caicedo-Torres W *et al.* 2020 In silico drug repurposing for the identification of potential candidate molecules against arboviruses infection. *Antiviral Res.* **173** 104668
- Mucke HAM 2018 Drug repurposing and artificial intelligence: from liaison to marriage. *Assay Drug Dev. Technol.* **16** 231
- Mukherjee R 2020 Global efforts on vaccines for COVID-19: since, sooner or later, we all will catch the coronavirus. *J. Biosci.* **45**
- Mumtaz N, Jimmerson LC, Bushman LR, Kiser JJ, Aron G *et al.* 2017 Cell-line dependent antiviral activity of sofosbuvir against Zika virus. *Antiviral Res.* **146** 161–163
- Muthaiyan M, Pushan SS, Naorem LD and Venkatesan A 2020 Understanding of Zaire ebolavirus-human protein interaction for drug repurposing. *Virusdisease* **31** 28–37
- Nabirotchkin S, Peluffo AE, Rinaudo P, Yu J, Hajj R *et al.* 2020 Next-generation drug repurposing using human genetics and network biology. *Curr. Opin. Pharmacol.* <https://doi.org/10.1016/j.coph.2019.12.004>
- Narayanan K, Huang C and Makino S 2008 SARS coronavirus accessory proteins. *Virus Res.* **133** 113–121
- Narayanan K, Ramirez SI, Lokugamage KG and Makino S 2015 Coronavirus nonstructural protein 1: common and distinct functions in the regulation of host and viral gene expression. *Virus Res.* **202** 89–100
- Nascimento ACA, Prudencio RBC and Costa IG 2019 A drug-target network-based supervised machine learning repurposing method allowing the use of multiple heterogeneous information sources. *Methods Mol. Biol.* **1903** 281–289
- Nath A, Kumari P and Chaube R 2018 Prediction of human drug targets and their interactions using machine learning methods: current and future perspectives. *Methods Mol. Biol.* **1762** 21–30
- Neogi U, Hill KJ, Ambikan AT, Heng X, Quinn TP *et al.* 2020 Feasibility of known RNA polymerase inhibitors as anti-SARS-CoV-2 drugs. *Pathogens* **9** <https://doi.org/10.3390/pathogens9050320>
- Nieto-Torres JL, Dediego ML, Alvarez E, Jimenez-Guardeno JM, Regla-Nava JA *et al.* 2011 Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein. *Virology* **415** 69–82
- Nieto-Torres JL, Verdía-Baguena C, Jimenez-Guardeno JM, Regla-Nava JA, Castano-Rodriguez C *et al.* 2015 Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. *Virology* **485** 330–339
- Nosengo N 2016 Can you teach old drugs new tricks? *Nature* **534** 314–316
- Nur SM, Hasan MA, Amin MA, Hossain M and Sharmin T 2015 Design of potential RNAi (miRNA and siRNA) molecules for middle east respiratory syndrome coronavirus (MERS-CoV) gene silencing by computational method. *Interdiscip. Sci.* **7** 257–265
- Omotade TO and Roy CR 2019 Manipulation of host cell organelles by intracellular pathogens. *Microbiol. Spectr.* **7** <https://doi.org/10.1128/microbiolspec.BAI-0022-2019>
- Oulas A, Minadakis G, Zachariou M, Sokratous K, Bourdakou MM *et al.* 2019 Systems Bioinformatics: increasing precision of computational diagnostics and therapeutics through network-based approaches. *Brief Bioinform.* **20** 806–824

- Pace JR, DeBerardinis AM, Sail V, Tacheva-Grigorova SK, Chan KA *et al.* 2016 Repurposing the clinically efficacious antifungal agent itraconazole as an anticancer chemotherapeutic. *J. Med. Chem.* **59** 3635–3649
- Pammolli F, Magazzini L and Riccaboni M 2011 The productivity crisis in pharmaceutical R&D. *Nat. Rev. Drug Discov.* **10**
- Pereira CA, Saye M, Reigada C, Silber AM, Labadie GR *et al.* 2020 Computational approaches for drug discovery against trypanosomatid-caused diseases. *Parasitology* **147** 611–633
- Pervushin K, Tan E, Parthasarathy K, Lin X, Jiang FL *et al.* 2009 Structure and inhibition of the SARS coronavirus envelope protein ion channel. *PLoS Pathog.* **5** e1000511
- Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA *et al.* 2020 Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* <https://doi.org/10.1038/s41586-020-2349-y>
- Pinzi L and Rastelli G 2019 Molecular docking: shifting paradigms in drug discovery. *Int. J. Mol. Sci.* **20** <https://doi.org/10.3390/ijms20184331>
- Pizzorno A, Padey B, Terrier O and Rosa-Calatrava M 2019 Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy. *Front. Immunol.* **10** 531
- Poterico JA and Mestanza O 2020 Genetic variants and source of introduction of SARS-CoV-2 in South America. *J. Med. Virol.* <https://doi.org/10.1002/jmv.26001>
- Praveen D, Puvvada RC and M VA 2020 Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. *Int. J. Antimicrob. Agents* <https://doi.org/10.1016/j.ijantimicag.2020.105967>
- Qing E, Hantak M, Perlman S and Gallagher T 2020 Distinct roles for sialoside and protein receptors in coronavirus infection. *mBio* **11** <https://doi.org/10.1128/mbio.02764-19>
- Rabinovich NR 2018 Ivermectin: repurposing an old drug to complement malaria vector control. *Lancet Infect. Dis.* **18** 584–585
- Rahman N, Basharat Z, Yousuf M, Castaldo G, Rastrelli L *et al.* 2020 Virtual screening of natural products against Type II transmembrane serine protease (TMPRSS2), the priming agent of coronavirus 2 (SARS-CoV-2). *Molecules* **25** <https://doi.org/10.3390/molecules25102271>
- Rainer TH 2004 Severe acute respiratory syndrome: clinical features, diagnosis, and management. *Curr. Opin. Pulm. Med.* **10** 159–165
- Rehman SU, Shafique L, Ihsan A and Liu Q 2020 Evolutionary trajectory for the emergence of novel coronavirus SARS-CoV-2. *Pathogens* **9** <https://doi.org/10.3390/pathogens9030240>
- Rossignol JF 2016 Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. *J. Infect. Public Health* **9** 227–230
- Saberian N, Peyvandipour A, Donato M, Ansari S and Draghici S 2019 A new computational drug repurposing method using established disease-drug pair knowledge. *Bioinformatics* **35** 3672–3678
- Saha P, Banerjee AK, Tripathi PP, Srivastava AK and Ray U 2020 A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity. *Biosci. Rep.* **40** <https://doi.org/10.1042/BSR20201312>
- Salata C, Calistri A, Alvisi G, Celestino M, Parolin C *et al.* 2019 Ebola virus entry: from molecular characterization to drug discovery. *Viruses* **11** <https://doi.org/10.3390/v11030274>
- Sanders JM, Monogue ML, Jodlowski TZ and Cutrell JB 2020 Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. *JAMA* <https://doi.org/10.1001/jama.2020.6019>
- Savarino A, Boelaert JR, Cassone A, Majori G and Cauda R 2003 Effects of chloroquine on viral infections: an old drug against today's diseases? *Lancet Infect. Dis.* **3** [https://doi.org/10.1016/S1473-3099\(03\)00806-5](https://doi.org/10.1016/S1473-3099(03)00806-5)
- Scannell JW, Blanckley A, Boldon H and Warrington B 2012 Diagnosing the decline in pharmaceutical R&D efficiency. *Nat. Rev. Drug Discov.*
- Schloer S, Goretzko J, Kuhn A, Brunotte L, Ludwig S *et al.* 2019 The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo. *Emerg. Microbes Infect.* **8** 80–93
- Schoergenhofer C, Jilma B, Stimpfl T, Karolyi M and Zoufaly A 2020 Pharmacokinetics of lopinavir and ritonavir in patients hospitalized with coronavirus disease 2019 (COVID-19). *Ann. Intern. Med.* <https://doi.org/10.7326/M20-1550>
- Shang J, Wan Y, Liu C, Yount B, Gully K *et al.* 2020 Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry. *PLoS Pathog.* **16** e1008392
- Shi H, Zhou C, He P, Huang S, Duan Y *et al.* 2020a Successful treatment of plasma exchange followed by intravenous immunoglobulin in a critically ill patient with 2019 novel coronavirus infection. *Int. J. Antimicrob. Agents* <https://doi.org/10.1016/j.ijantimicag.2020.105974>
- Shi W, Chen X and Deng L 2020b A review of recent developments and progress in computational drug repositioning. *Curr. Pharm. Des.* <https://doi.org/10.2174/1381612826666200116145559>
- Shirato K, Kawase M and Matsuyama S 2013 Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. *J. Virol.* **87** 12552–12561
- Simmons G, Bertram S, Glowacka I, Steffen I, Chaipan C *et al.* 2011 Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion. *Virology* **413** 265–274
- Sisk JM, Frieman MB and Machamer CE 2018 Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. *J. Gen. Virol.* **99** 619–630

- Skinner D, Marro BS and Lane TE 2019 Chemokine CXCL10 and Coronavirus-Induced Neurologic Disease. *Viral Immunol.* **32** 25–37
- Sohrab SS, El-Kafrawy SA, Mirza Z, Kamal MA and Azhar EI 2018 Design and delivery of therapeutic siRNAs: application to MERS-coronavirus. *Curr. Pharm. Des.* **24** 62–77
- Song F, Shi N, Shan F, Zhang Z, Shen J *et al.* 2020 Emerging 2019 novel coronavirus (2019-nCoV) pneumonia. *Radiology* **295** 210–217
- Song Z, Yang Y, Wang L, Wang K, Ran L *et al.* 2019 EIF4A2 interacts with the membrane protein of transmissible gastroenteritis coronavirus and plays a role in virus replication. *Res. Vet. Sci.* **123** 39–46
- Sternberg A, McKee DL and Naujokat C 2020 Novel drugs targeting the SARS-CoV-2/COVID-19 machinery. *Curr. Top. Med. Chem.* <https://doi.org/10.2174/1568026620999200517043137>
- Stobart CC, Sexton NR, Munjal H, Lu X, Molland KL *et al.* 2013 Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity. *J. Virol.* **87** 12611–12618
- Strittmatter SM 2014 Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks. *Nat. Med.* **20** 590–591
- Stupnikov A, O'Reilly PG, McInerney CE, Roddy AC, Dunne PD *et al.* 2018 Impact of variable rna-sequencing depth on gene expression signatures and target compound robustness: case study examining brain tumor (Glioma) disease progression. *JCO Precis. Oncol.* **2** <https://doi.org/10.1200/PO.18.00014>
- Su YJ and Lai YC 2020 Comparison of clinical characteristics of coronavirus disease (COVID-19) and severe acute respiratory syndrome (SARS) as experienced in Taiwan. *Travel. Med. Infect. Dis.* <https://doi.org/10.1016/j.tmaid.2020.101625>
- Sung JJ, Wu A, Joynt GM, Yuen KY, Lee N *et al.* 2004 Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. *Thorax* **59** 414–420
- Tai W, He L, Zhang X, Pu J, Voronin D *et al.* 2020 Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. *Cell Mol. Immunol.* <https://doi.org/10.1038/s41423-020-0400-4>
- Talevi A and Bellera CL 2020 Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. *Expert Opin. Drug Discov.* **15** 397–401
- Tanaka Y, Sato Y and Sasaki T 2013 Suppression of coronavirus replication by cyclophilin inhibitors. *Viruses* **5** 1250–1260
- te Velthuis AJ, van den Worm SH and Snijder EJ 2012 The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension. *Nucl. Acids Res.* **40** 1737–1747
- Tian X, Li C, Huang A, Xia S, Lu S *et al.* 2020 Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *Emerg. Microbes Infect.* **9** 382–385
- Tortorici MA and Vesler D 2019 Structural insights into coronavirus entry. *Adv. Virus Res.* **105** 93–116
- Trosset JY and Cave C 2019 In silico drug-target profiling. *Methods Mol. Biol.* **1953** 89–103
- Tsang K and Seto WH 2004 Severe acute respiratory syndrome: scientific and anecdotal evidence for drug treatment. *Curr. Opin. Investig. Drugs* **5** 179–185
- Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T *et al.* 2003 A cluster of cases of severe acute respiratory syndrome in Hong Kong. *N. Engl. J. Med.* **348** 1977–1985
- Tsang KW and Lam WK 2003 Management of severe acute respiratory syndrome: the Hong Kong University experience. *Am. J. Respir. Crit. Care Med.* **168** 417–424
- Tsubamoto H, Ueda T, Inoue K, Sakata K, Shibahara H *et al.* 2017 Repurposing itraconazole as an anticancer agent. *Oncol. Lett.* **14** 1240–1246
- Tufan A, Avanoglu Guler A and Matucci-Cerinic M 2020 COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. *Turk. J. Med. Sci.* **50** 620–632
- Uitdehaag JCM, Kooijman JJ, de Roos J, Prinsen MBW, Dylus J *et al.* 2019 Combined cellular and biochemical profiling to identify predictive drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017. *Mol. Cancer Ther.* **18** 470–481
- Urquhart L 2018 Market watch: top drugs and companies by sales in 2017. *Nat. Rev. Drug Discov.* **17**
- van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS *et al.* 2012 Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. *mBio* **3** <https://doi.org/10.1128/mbio.00473-12>
- Veljkovic V, Loiseau PM, Figadere B, Glisic S, Veljkovic N *et al.* 2015 Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. *F1000Res* **4** 34
- Veronese N, Demurtas J, Yang L, Tonelli R, Barbagallo M *et al.* 2020 Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. *Front. Med. (Lausanne)* **7** 170
- Wang C, Hua C, Xia S, Li W, Lu L *et al.* 2019 Combining a fusion inhibitory peptide targeting the MERS-CoV S2 Protein HR1 domain and a neutralizing antibody specific for the S1 protein receptor-binding domain (RBD) showed potent synergism against pseudotyped MERS-CoV with or without mutations in RBD. *Viruses* **11** <https://doi.org/10.3390/v11010031>

- Wang C, Li W, Drabek D, Okba NMA, van Haperen R *et al.* 2020a A human monoclonal antibody blocking SARS-CoV-2 infection. *Nat. Commun.* **11** 2251
- Wang D, Hu B, Hu C, Zhu F, Liu X *et al.* 2020b Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* <https://doi.org/10.1001/jama.2020.1585>
- Wang M 2020 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* **30** <https://doi.org/10.1038/s41422-020-0282-0>
- Wang M, Cao R, Zhang L, Yang X, Liu J *et al.* 2020c Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* **30** <https://doi.org/10.1038/s41422-020-0282-0>
- Wen M, Zhang Z, Niu S, Sha H, Yang R *et al.* 2017 Deep-learning-based drug-target interaction prediction. *J. Proteome Res.* **16** 1401–1409
- Wong KT, Antonio GE, Hui DS, Lee N, Yuen EH *et al.* 2003 Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. *Radiology* **228** 401–406
- Wrapp D 2020 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367** <https://doi.org/10.1126/science.abb2507>
- Wu G, Liu J and Yue X 2019 Prediction of drug-disease associations based on ensemble meta paths and singular value decomposition. *BMC Bioinform.* **20** 134
- Wu R, Wang L, Kuo HD, Shannar A, Peter R *et al.* 2020a An update on current therapeutic drugs treating COVID-19. *Curr. Pharmacol. Rep.* <https://doi.org/10.1007/s40495-020-00216-7>
- Wu Y, Li C, Xia S, Tian X, Kong Y *et al.* 2020b Identification of human single-domain antibodies against SARS-CoV-2. *Cell Host. Microbe* <https://doi.org/10.1016/j.chom.2020.04.023>
- Xia S, Lan Q, Pu J, Wang C, Liu Z *et al.* 2019a Potent MERS-CoV fusion inhibitory peptides identified from HR2 domain in spike protein of bat coronavirus HKU4. *Viruses* **11** <https://doi.org/10.3390/v11010056>
- Xia S, Yan L, Xu W, Agrawal AS, Algaissi A *et al.* 2019b A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. *Sci. Adv.* **5** eaav4580
- Xia X 2017 Bioinformatics and drug discovery. *Curr. Top Med. Chem.* **17** 1709–1726
- Xie M and Chen Q 2020a Insight into 2019 novel coronavirus—an updated interim review and lessons from SARS-CoV and MERS-CoV. *Int. J. Infect. Dis.* **94** 119–124
- Xie M and Chen Q 2020b Insight into 2019 novel coronavirus - an updated intrim review and lessons from SARS-CoV and MERS-CoV. *Int. J. Infect. Dis.* <https://doi.org/10.1016/j.ijid.2020.03.071>
- Yang H, Xie W, Xue X, Yang K, Ma J *et al.* 2005 Design of wide-spectrum inhibitors targeting coronavirus main proteases. *PLoS Biol.* **3** e324
- Yang M, Luo H, Li Y, Wu FX and Wang J 2019 Overlap matrix completion for predicting drug-associated indications. *PLoS Comput. Biol.* **15** e1007541 <https://doi.org/10.1371/journal.pcbi.1007541>
- Yao X, Ye F, Zhang M, Cui C, Huang B *et al.* 2020 In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin. Infect. Dis.* <https://doi.org/10.1093/cid/ciaa237>
- Yildirim O, Gottwald M, Schuler P and Michel MC 2016 Opportunities and challenges for drug development: public-private partnerships, adaptive designs and big data. *Front. Pharmacol.* **7** 461
- Yin C 2020 Genotyping coronavirus SARS-CoV-2: methods and implications. *Genomics* <https://doi.org/10.1016/j.ygeno.2020.04.016>
- Zai CC, Tiwari AK, Zai GC, de Luca V, Shaikh SA *et al.* 2018 Sequence analysis of drug target genes with suicidal behavior in bipolar disorder patients. *Mol. Neuropsychiatry* **4** 1–6
- Zeng X, Zhu S, Hou Y, Zhang P, Li L *et al.* 2020 Network-based prediction of drug-target interactions using an arbitrary-order proximity embedded deep forest. *Bioinformatics* **36** 2805–2812
- Zha L, Li S, Pan L, Tefsen B, Li Y *et al.* 2020 Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). *Med. J. Aust.* <https://doi.org/10.5694/mja2.50577>
- Zhang J, Han Y, Shi H, Chen J, Zhang X *et al.* 2020a Swine acute diarrhea syndrome coronavirus-induced apoptosis is caspase- and cyclophilin D- dependent. *Emerg. Microbes Infect.* **9** 439–456
- Zhang S, Yi C, Li C, Zhang F, Peng J *et al.* 2019 Chloroquine inhibits endosomal viral RNA release and autophagy-dependent viral replication and effectively prevents maternal to fetal transmission of Zika virus. *Antiviral Res.* **169** 104547
- Zhang WF, Stephen P, Theriault JF, Wang R and Lin SX 2020b Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to target new outbreaks. *J. Phys. Chem. Lett.* <https://doi.org/10.1021/acs.jpclett.0c00571>
- Zhang YZ and Holmes EC 2020 A genomic perspective on the origin and emergence of SARS-CoV-2. *Cell* **181** 223–227
- Zhao K and So HC 2019 Drug repositioning for schizophrenia and depression/anxiety disorders: a machine learning approach leveraging expression data. *IEEE J. Biomed. Health Inform.* **23** 1304–1315
- Zhao Z, Zhang F, Xu M, Huang K, Zhong W *et al.* 2003 Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. *J. Med. Microbiol.* **52** 715–720
- Zhou L, Li Z, Yang J, Tian G, Liu F *et al.* 2019 Revealing drug-target interactions with computational models and algorithms. *Molecules* **24** <https://doi.org/10.3390/molecules24091714>

- Zhou N, Pan T, Zhang J, Li Q, Zhang X *et al.* 2016 Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). *J. Biol. Chem.* **291** 9218–9232
- Zhou P, Yang X, Wang X, Hu B, Zhang L *et al.* 2020a A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579** <https://doi.org/10.1038/s41586-020-2012-7>
- Zhou Y, Hou Y, Shen J, Huang Y, Martin W *et al.* 2020b Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discov.* **6** 14
- Zimmermann P and Curtis N 2020 Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. *Pediatr. Infect. Dis. J.* **39** 355–368
- Zumla A, Chan JF, Azhar EI, Hui DS and Yuen KY 2016 Coronaviruses - drug discovery and therapeutic options. *Nat. Rev. Drug Discov.* **15** 327–347

Corresponding editor: BJ RAO